ClinicalTrials.gg
TerminatedNCT00996892Updated Dec 30, 2016Results posted

Safety, Tolerability and Pharmacokinetics of Cobimetinib in Combination With Pictilisib in Patients With Locally Advanced or Metastatic Solid Tumors

A Phase 1 interventional study of Cobimetinib and Pictilisib in Solid Tumors, sponsored by Genentech, Inc.. Terminated at 6 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-12-30.

Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 1, Interventional, and Treatment

Why this study was terminated
A recommended Phase 2 dose and schedule was not identified and the study was terminated before initiation of Stage 2B.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
178
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is an open-label, multicenter, Phase Ib dose-escalation study designed to assess the safety, tolerability and pharmacokinetics of oral dosing of cobimetinib and pictilisib administered in combination in patients with locally advanced or metastatic solid tumors.

02

Conditions studied

  • Solid Tumors

Keywords

  • GDC0941
  • GDC0973
  • MEK
  • MEK Inhibitor
  • PI3K
  • PI3K Inhibitor
  • PI3 Kinase
  • PI3 Kinase Inhibitor
03

In context

Lead sponsor

Genentech, Inc. is the lead sponsor of 517 studies on the registry; 20 are open to participants now.

Of its 95 completed or terminated interventional studies of FDA-regulated products, 52 (55%) have results posted.

First submitted after Genentech, Inc. became part of Hoffmann-La Roche.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically documented, locally advanced or solid tumors for which standard therapy either does not exist or has proven ineffective or intolerable
  • Evaluable disease or disease measurable per (RECIST)
  • greater than or equal to (>=) 12 weeks
  • Adequate hematologic and end organ function
  • Agreement to use an effective form of for the duration of the study

Exclusion criteria

Exclusion Criteria:

  • History of prior significant toxicity from another mitogen-activated protein kinase (MEK) pathway inhibitor requiring discontinuation of treatment
  • History of prior significant toxicity from another phosphoinositide 3-kinase (PI3K) pathway inhibitor requiring discontinuation of treatment
  • Allergy or to components of the cobimetinib or pictilisib formulations
  • Palliative radiotherapy within 2 weeks prior to first dose of study drug treatment in Cycle 1
  • Experimental therapy within 4 weeks prior to first dose of study drug treatment in Cycle 1
  • Major surgical procedure or significant traumatic injury within 4 weeks prior to first dose of study drug treatment in Cycle 1, or anticipation of the need for major surgery during the course of study treatment
  • Prior anti-cancer therapy within 28 days before the first dose of study drug treatment in Cycle 1
  • History of diabetes requiring daily medication, or history of Grade >= 3 fasting hyperglycemia
  • Current severe, uncontrolled systemic disease
  • History of cardiac or pulmonary dysfunction
  • History of malabsorption or other condition that would interfere with enteral absorption
  • Clinically significant history of liver disease (including cirrhosis), current alcohol abuse, or current known active infection with (HIV), virus, or virus
  • Any condition requiring anticoagulants, such as warfarin, heparin, or thrombolytics
  • Active disease
  • Uncontrolled ascites requiring weekly large volume paracentesis for 3 consecutive weeks prior to enrollment
  • Pregnancy, lactation, or breastfeeding
  • Known that are untreated, symptomatic, or require therapy to control symptoms
  • No other history of or ongoing that would potentially interfere with the interpretation of the pharmacodynamic or efficacy assays
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
178 participants (actual)

Study arms

  • Experimental
    Dose Escalation Stage 1: Cobimetinib + Pictilisib

    Participants will receive cobimetinib capsules (at a starting dose of 20 milligrams \[mg\]) and pictilisib capsules (at a starting dose of 80 mg) from Days 1 to 21 and then 7 days off study drugs from Days 22 to 28 in continuous 28-day cycles. Doses will be increased to identify maximum tolerated dose (MTD) or potential recommended Phase 2 dose (RP2D). Treatment will continue until disease progression, unacceptable toxicity, or any other discontinuation criterion meets.

    Drug: Cobimetinib · Drug: Pictilisib

  • Experimental
    Dose Escalation Stage 1A: Cobimetinib + Pictilisib

    Participants will receive cobimetinib capsules (at a starting dose of 100 mg) on Days 1, 4, 8, 11, 15, and 18 and pictilisib capsules (at a starting dose of 130 mg) from Days 1 to 21 and then 7 days off study drugs from Days 22 to 28 in continuous 28-day cycles. Doses will be increased to identify MTD or potential RP2D.Treatment will continue until disease progression, unacceptable toxicity, or any other discontinuation criterion meets.

    Drug: Cobimetinib · Drug: Pictilisib

  • Experimental
    Dose Escalation Stage 1B: Cobimetinib + Pictilisib

    Participants will receive cobimetinib capsules (at a starting dose of 40 mg) and pictilisib capsules (at a starting dose of 130 mg) from Days 1 to 7 and then from Days 15 to 21 in continuous 28-day cycles. Participants will be off study drugs from Days 8 to 14 and from Days 22 to 28. Treatment will continue until disease progression, unacceptable toxicity, or any other discontinuation criterion meets.

    Drug: Cobimetinib · Drug: Pictilisib

  • Experimental
    Dose Expansion Stage 2: Cobimetinib + Pictilisib

    Participants will received cobimetinib capsules and pictilisib capsules from Days 1 to 21 and then 7 days off study drugs from Days 22 to 28 in continuous 28-day cycles, at doses identified as MTD/potential RP2D from Stage 1. Treatment will continue until disease progression, unacceptable toxicity, or any other discontinuation criterion meets. This indication specific cohort will include participants with Kirsten rat sarcoma viral oncogene homolog (KRAS) mutant non-small cell lung cancer (NSCLC); epidermal growth factor receptor (EGFR) T790M mutant and EGFR inhibitor-progressing NSCLC; pancreatic adenocarcinoma; and KRAS mutant colorectal cancer (CRC).

    Drug: Cobimetinib · Drug: Pictilisib

  • Experimental
    Dose Expansion Stage 2A: Cobimetinib + Pictilisib

    Participants received cobimetinib capsules on Days 1, 4, 8, 11, 15, and 18 and pictilisib capsules from Days 1 to 21 and then 7 days off study drugs from Days 22 to 28 in continuous 28-day cycles, at doses identified as MTD/potential RP2D from Stage 1A. Treatment will continue until disease progression, unacceptable toxicity, or any other discontinuation criterion meets. This indication specific cohort will include participants with KRAS mutant NSCLC; EGFR T790M mutant and EGFR inhibitor-progressing NSCLC; pancreatic adenocarcinoma; KRAS mutant CRC, and KRAS mutant endometrioid carcinoma.

    Drug: Cobimetinib · Drug: Pictilisib

  • Experimental
    Dose Expansion Stage 2B: Cobimetinib + Pictilisib

    Participants will receive cobimetinib capsules and pictilisib capsules from Days 1 to 7 and then from Days 15 to 21 in continuous 28-day cycles, at doses identified as MTD/potential RP2D from Stage 1B. Participants will be off study drugs from Days 8 to 14 and from Days 22 to 28. Treatment will continue until disease progression, unacceptable toxicity, or any other discontinuation criterion meets. This indication specific cohort will include participants with KRAS mutant endometrioid carcinoma.

    Drug: Cobimetinib · Drug: Pictilisib

Interventions

  • Repeated oral dosing.

    Also known as: GDC-0973, XL518

  • Repeated oral dosing.

    Also known as: GDC-0941

06

What researchers measure

Primary outcomes

  1. Number of Participants With Dose-Limiting Toxicities (DLTs) During Dose Escalation Stages 1, 1A and 1B

    DLT was defined as 1 of the following toxicities considered treatment related by Investigator: Grade ≥3 non-hematologic, non-hepatic organ toxicity, excluding the following: Grade 3 nausea, vomiting, or diarrhea that resolved to Grade ≤1 within 7 days, Grade 3 rash or Grade ≥3 fatigue that resolved to Grade ≤2 within 7 days, Grade ≥3 hyperglycemia or lipid profile results that occurred during non-fasting conditions, Grade 3 or 4 elevation of serum creatine phosphokinase levels or Grade 3 non clinically significant (as assessed by Investigator) laboratory abnormality that was asymptomatic; Grade ≥3 febrile neutropenia; Grade ≥4 neutropenia (absolute neutrophil count \<500/microliter) lasting \>5 days; Grade ≥4 thrombocytopenia lasting \>48 hours; Grade ≥4 anemia; Grade ≥3 total bilirubin, hepatic transaminase, alkaline phosphatase, lasting \>72 hours; Grade ≥2 diffusion capacity of the lung for carbon monoxide concomitant with an absolute decrease of ≥20 percentage points from baseline.

    Time frame: Cohorts 1-3: Day 1 to Day 35, All other cohorts: Day 1 to Day 28

  2. Maximum Tolerated Combination Doses of Cobimetinib and Pictilisib During Dose-Escalation Stages 1, 1A and 1B

    MTD was determined (by Investigator) based on the DLTs, as well as adverse events (AEs) in dose-escalation Stages 1, 1A, and 1B that did not meet protocol-defined DLT criteria but indicated intolerability of a given dose combination. Separate combination MTDs were determined for each dose-escalation stage. DLT was defined as 1 of the following toxicities considered treatment related by Investigator: Grade ≥3 non-hematologic, non-hepatic organ toxicity; Grade ≥3 febrile neutropenia; Grade ≥4 neutropenia (absolute neutrophil count \<500/microliter) lasting \>5 days; Grade ≥4 thrombocytopenia lasting \>48 hours; Grade ≥4 anemia; Grade ≥3 total bilirubin, hepatic transaminase, alkaline phosphatase, lasting \>72 hours; Grade ≥2 diffusion capacity of the lung for carbon monoxide concomitant with an absolute decrease of ≥20 percentage points from baseline.

    Time frame: Cohorts 1-3: Day 1 to Day 35, All other cohorts: Day 1 to Day 28

  3. Time of Maximum Concentration (Tmax) of Cobimetinib on Day 3 - Stage 1, Cohorts 1-3

    Time frame: 0-4 hours pre-cobimetinib (Pr-C) dose, 0.5, 2, 4, 6 hours post-cobimetinib (Po-C) dose on Day 3, Day 4

  4. Maximum Plasma Concentration (Cmax) of Cobimetinib on Day 3 - Stage 1, Cohorts 1-3

    Time frame: 0-4 hours Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Day 3, Day 4

  5. Area Under the Concentration-Time Curve From Time 0 to 24 Hours Post-Dose (AUC0-24) of Cobimetinib on Day 3 - Stage 1, Cohorts 1-3

    Time frame: 0-4 hours Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Day 3, Day 4

  6. Tmax of Pictilisib on Day 1 - Stage 1, Cohorts 1-3

    Time frame: 0-4 hours pre-pictilisib (Pr-P) dose, 0.5, 2, 4, 6 hours post-pictilisib (Po-P) dose on Day 1, Day 2, 0-4 hours Pr-C dose on Day 3

  7. Cmax of Pictilisib on Day 1 - Stage 1, Cohorts 1-3

    Time frame: 0-4 hours Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Day 1, Day 2, 0-4 hours Pr-C dose on Day 3

  8. AUC0-24 of Pictilisib on Day 1 - Stage 1, Cohorts 1-3

    Time frame: 0-4 hours Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Day 1, Day 2, 0-4 hours Pr-C dose on Day 3

Secondary outcomes

  1. Tmax of Cobimetinib on Cycle 1 Day 1 (Cycle 1 Day 8 for Cohorts 1-3) - Stage 1 All Cohorts

    Time frame: Cohorts 1-3: Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 8, Cycle 1 Days 9, 15, 21; Cohorts 4-6A: Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 1, Cycle 1 Day 2, 8, 14

  2. Cmax of Cobimetinib on Cycle 1 Day 1 (Cycle 1 Day 8 for Cohorts 1-3) - Stage 1 All Cohorts

    Time frame: Cohorts 1-3: Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 8, Cycle 1 Days 9, 15, 21; Cohorts 4-6A: Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 1, Cycle 1 Day 2, 8, 14

  3. AUC0-24 of Cobimetinib on Cycle 1 Day 1 (Cycle 1 Day 8 for Cohorts 1-3) - Stage 1 All Cohorts

    Time frame: Cohorts 1-3: Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 8, Cycle 1 Days 9; Cohorts 4-6A: Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 1, Cycle 1 Day 2

  4. Tmax of Cobimetinib on Cycle 1 Day 21 (Cycle 1 Day 28 for Cohorts 1-3) - Stage 1 All Cohorts

    Time frame: Cohorts 1-3: Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 28, Cycle 1 Day 29, Cycle 2 Days 1, 15, 21; Cohorts 4-6A: Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 21, Cycle 1 Day 22, Cycle 2 Days 1, 15, 21

  5. Cmax of Cobimetinib on Cycle 1 Day 21 (Cycle 1 Day 28 for Cohorts 1-3) - Stage 1 All Cohorts

    Time frame: Cohorts 1-3: Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 28, Cycle 1 Day 29, Cycle 2 Days 1, 15, 21; Cohorts 4-6A: Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 21, Cycle 1 Day 22, Cycle 2 Days 1, 15, 21

  6. AUC0-24 of Cobimetinib on Cycle 1 Day 21 (Cycle 1 Day 28 for Cohorts 1-3) - Stage 1 All Cohorts

    Time frame: Cohorts 1-3: Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 28, Cycle 1 Day 29; Cohorts 4-6A: Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 21, Cycle 1 Day 22

  7. Terminal Half-life (t1/2) of Cobimetinib on Cycle 1 Day 21 (Cycle 1 Day 28 for Cohorts 1-3) - Stage 1 All Cohorts

    Half-life is the time measured for the plasma concentration to decrease by one half.

    Time frame: Cohorts 1-3: Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 28, Cycle 1 Day 29, Cycle 2 Days 1, 15, 21; Cohorts 4-6A: Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 21, Cycle 1 Day 22, Cycle 2 Days 1, 15, 21

  8. Apparent Clearance (CL/F) of Cobimetinib on Cycle 1 Day 21 (Cycle 1 Day 28 for Cohorts 1-3) - Stage 1 All Cohorts

    Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.

    Time frame: Cohorts 1-3: Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 28, Cycle 1 Day 29, Cycle 2 Days 1, 15, 21; Cohorts 4-6A: Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 21, Cycle 1 Day 22, Cycle 2 Days 1, 15, 21

  9. Accumulation Ratio of Cobimetinib on Cycle 1 Day 21 (Cycle 1 Day 28 for Cohorts 1-3) - Stage 1 All Cohorts

    Accumulation ratio was calculated as: AUC0-24 at Cycle 1 Day 21 (Cycle 1 Day 28 for Cohorts 1-3) divided by AUC0-24 at Cycle 1 Day 1 (Cycle 1 Day 8 for Cohorts 1-3).

    Time frame: Cohorts 1-3: Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Days 8 and 28, Cycle 1 Days 9, 29; Cohorts 4-6A: Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Days 1 and 21, Cycle 1 Days 2, 22

  10. Tmax of Pictilisib on Cycle 1 Day 1 (Cycle 1 Day 8 for Cohorts 1-3) - Stage 1 All Cohorts

    Time frame: Cohorts 1-3: Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 8, Cycle 1 Day 9, 15, 21; Cohorts 4-6A: Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 1, Cycle 1 Day 2, 8, 14

  11. Cmax of Pictilisib on Cycle 1 Day 1 (Cycle 1 Day 8 for Cohorts 1-3) - Stage 1 All Cohorts

    Time frame: Cohorts 1-3: Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 8, Cycle 1 Day 9, 15, 21; Cohorts 4-6A: Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 1, Cycle 1 Day 2, 8, 14

  12. AUC0-24 of Pictilisib on Cycle 1 Day 1 (Cycle 1 Day 8 for Cohorts 1-3) - Stage 1 All Cohorts

    Time frame: Cohorts 1-3: Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 8, Cycle 1 Day 9; Cohorts 4-6A: Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 1, Cycle 1 Day 2

  13. Tmax of Pictilisib on Cycle 1 Day 21 (Cycle 1 Day 28 for Cohorts 1-3) - Stage 1 All Cohorts

    Time frame: Cohorts 1-3: Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 28, Cycle 1 Day 29, Cycle 2 Days 1, 15, 21; Cohorts 4-6A: Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 21, Cycle 1 Day 22, Cycle 2 Days 1, 15, 21

  14. Cmax of Pictilisib on Cycle 1 Day 21 (Cycle 1 Day 28 for Cohorts 1-3) - Stage 1 All Cohorts

    Time frame: Cohorts 1-3: Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 28, Cycle 1 Day 29, Cycle 2 Days 1, 15, 21; Cohorts 4-6A: Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 21, Cycle 1 Day 22, Cycle 2 Days 1, 15, 21

  15. AUC0-24 of Pictilisib on Cycle 1 Day 21 (Cycle 1 Day 28 for Cohorts 1-3) - Stage 1 All Cohorts

    Time frame: Cohorts 1-3: Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 28, Cycle 1 Day 29; Cohorts 4-6A: Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 21, Cycle 1 Day 22

  16. t1/2 of Pictilisib on Cycle 1 Day 21 (Cycle 1 Day 28 for Cohorts 1-3) - Stage 1 All Cohorts

    Half-life is the time measured for the plasma concentration to decrease by one half. As planned, summary statistics were not derived if fewer than 3 participants had available data; however, if the number of participants analyzed = 1, then the observed data of the single participant was reported as geometric mean.

    Time frame: Cohorts 1-3: Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 28, Cycle 1 Day 29, Cycle 2 Days 1, 15, 21; Cohorts 4-6A: Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 21, Cycle 1 Day 22, Cycle 2 Days 1, 15, 21

  17. CL/F of Pictilisib on Cycle 1 Day 21 (Cycle 1 Day 28 for Cohorts 1-3) - Stage 1 All Cohorts

    Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.

    Time frame: Cohorts 1-3: Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 28, Cycle 1 Day 29, Cycle 2 Days 1, 15, 21; Cohorts 4-6A: Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 21, Cycle 1 Day 22, Cycle 2 Days 1, 15, 21

  18. Accumulation Ratio of Pictilisib on Cycle 1 Day 21 (Cycle 1 Day 28 for Cohorts 1-3) - Stage 1 All Cohorts

    Accumulation ratio was calculated as: AUC0-24 at Cycle 1 Day 21 (Cycle 1 Day 28 for Cohorts 1-3) divided by AUC0-24 at Cycle 1 Day 1 (Cycle 1 Day 8 for Cohorts 1-3).

    Time frame: Cohorts 1-3: Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Days 8 and 28, Cycle 1 Days 9, 29; Cohorts 4-6A: Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Days 1 and 21, Cycle 1 Day 2, 22

  19. Tmax of Cobimetinib on Cycle 1 Day 1 - Stage 1A All Cohorts

    Time frame: Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 1, Cycle 1 Days 2, 8, 15-17

  20. Cmax of Cobimetinib on Cycle 1 Day 1 - Stage 1A All Cohorts

    Time frame: Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 1, Cycle 1 Days 2, 8, 15-17

  21. AUC0-24 of Cobimetinib on Cycle 1 Day 1 - Stage 1A All Cohorts

    Time frame: Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 1, Cycle 1 Days 2

  22. Tmax of Cobimetinib on Cycle 1 Day 18 - Stage 1A All Cohorts

    Time frame: Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 18, Cycle 1 Day 19, Cycle 2 Days 1, 15, 21

  23. Cmax of Cobimetinib on Cycle 1 Day 18 - Stage 1A All Cohorts

    Time frame: Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 18, Cycle 1 Day 19, Cycle 2 Days 1, 15, 21

  24. AUC0-24 of Cobimetinib on Cycle 1 Day 18 - Stage 1A All Cohorts

    Time frame: Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 18, Cycle 1 Day 19

  25. t1/2 of Cobimetinib on Cycle 1 Day 18 - Stage 1A All Cohorts

    Half-life is the time measured for the plasma concentration to decrease by one half.

    Time frame: Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 18, Cycle 1 Day 19, Cycle 2 Days 1, 15, 21

  26. CL/F of Cobimetinib on Cycle 1 Day 18 - Stage 1A All Cohorts

    Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.

    Time frame: Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 18, Cycle 1 Day 19, Cycle 2 Days 1, 15, 21

  27. Accumulation Ratio of Cobimetinib on Cycle 1 Day 18 - Stage 1A All Cohorts

    Accumulation ratio was calculated as: AUC0-24 at Cycle 1 Day 18 divided by AUC0-24 at Cycle 1 Day 1.

    Time frame: Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Days 1 and 18, Cycle 1 Days 2, 19

  28. Tmax of Pictilisib on Cycle 1 Day 1 - Stage 1A All Cohorts

    Time frame: Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 1, Cycle 1 Days 2, 8, 15-17

  29. Cmax of Pictilisib on Cycle 1 Day 1 - Stage 1A All Cohorts

    Time frame: Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 1, Cycle 1 Days 2, 8, 15-17

  30. AUC0-24 of Pictilisib on Cycle 1 Day 1 - Stage 1A All Cohorts

    Time frame: Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 1, Cycle 1 Days 2

  31. Tmax of Pictilisib on Cycle 1 Day 18 - Stage 1A All Cohorts

    Time frame: Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 18, Cycle 1 Day 19, Cycle 2 Days 1, 15, 21

  32. Cmax of Pictilisib on Cycle 1 Day 18 - Stage 1A All Cohorts

    Time frame: Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 18, Cycle 1 Day 19, Cycle 2 Days 1, 15, 21

  33. AUC0-24 of Pictilisib on Cycle 1 Day 18 - Stage 1A All Cohorts

    Time frame: Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 18, Cycle 1 Day 19

  34. t1/2 of Pictilisib on Cycle 1 Day 18 - Stage 1A All Cohorts

    Half-life is the time measured for the plasma concentration to decrease by one half. As planned, summary statistics were not derived if fewer than 3 participants had available data; however, if the number of participants analyzed = 1, then the observed data of the single participant was reported as geometric mean.

    Time frame: Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 18, Cycle 1 Day 19, Cycle 2 Days 1, 15, 21

  35. CL/F of Pictilisib on Cycle 1 Day 18 - Stage 1A All Cohorts

    Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.

    Time frame: Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 18, Cycle 1 Day 19, Cycle 2 Days 1, 15, 21

  36. Accumulation Ratio of Pictilisib on Cycle 1 Day 18 - Stage 1A All Cohorts

    Accumulation ratio was calculated as: AUC0-24 at Cycle 1 Day 18 divided by AUC0-24 at Cycle 1 Day 1.

    Time frame: Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Days 1 and 18, Cycle 1 Days 2, 19

  37. Tmax of Cobimetinib on Cycle 1 Day 1 - Stage 1B All Cohorts

    Time frame: Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 1, Cycle 1 Day 2

  38. Cmax of Cobimetinib on Cycle 1 Day 1 - Stage 1B All Cohorts

    Time frame: Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 1, Cycle 1 Day 2

  39. AUC0-24 of Cobimetinib on Cycle 1 Day 1 - Stage 1B All Cohorts

    Time frame: Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 1, Cycle 1 Day 2

  40. Tmax of Cobimetinib on Cycle 1 Day 21 - Stage 1B All Cohorts

    Time frame: Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 21, Cycle 1 Day 22

  41. Cmax of Cobimetinib on Cycle 1 Day 21 - Stage 1B All Cohorts

    Time frame: Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 21, Cycle 1 Day 22

  42. AUC0-24 of Cobimetinib on Cycle 1 Day 21 - Stage 1B All Cohorts

    Time frame: Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 21, Cycle 1 Day 22

  43. CL/F of Cobimetinib on Cycle 1 Day 21 - Stage 1B All Cohorts

    Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.

    Time frame: Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 21, Cycle 1 Day 22

  44. Accumulation Ratio of Cobimetinib on Cycle 1 Day 21 - Stage 1B All Cohorts

    Accumulation ratio was calculated as: AUC0-24 at Cycle 1 Day 21 divided by AUC0-24 at Cycle 1 Day 1.

    Time frame: Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Days 1 and 21, Cycle 1 Days 2 and 22

  45. Tmax of Pictilisib on Cycle 1 Day 1 - Stage 1B All Cohorts

    Time frame: Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 1, Cycle 1 Day 2

  46. Cmax of Pictilisib on Cycle 1 Day 1 - Stage 1B All Cohorts

    Time frame: Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 1, Cycle 1 Day 2

  47. AUC0-24 of Pictilisib on Cycle 1 Day 1 - Stage 1B All Cohorts

    Time frame: Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 1, Cycle 1 Day 2

  48. Tmax of Pictilisib on Cycle 1 Day 21 - Stage 1B All Cohorts

    Time frame: Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 21, Cycle 1 Day 22

  49. Cmax of Pictilisib on Cycle 1 Day 21 - Stage 1B All Cohorts

    Time frame: Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 21, Cycle 1 Day 22

  50. AUC0-24 of Pictilisib on Cycle 1 Day 21 - Stage 1B All Cohorts

    Time frame: Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 21, Cycle 1 Day 22

  51. CL/F of Pictilisib on Cycle 1 Day 21 - Stage 1B All Cohorts

    Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.

    Time frame: Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 21, Cycle 1 Day 22

  52. Accumulation Ratio of Pictilisib on Cycle 1 Day 21 - Stage 1B All Cohorts

    Accumulation ratio was calculated as: AUC0-24 at Cycle 1 Day 21 divided by AUC0-24 at Cycle 1 Day 1.

    Time frame: Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Days 1 and 21, Cycle 1 Days 2 and 22

  53. Tmax of Cobimetinib on Cycle 1 Day 1 - Stage 2 Individual Indication Specific Cohorts

    Stage 2 PK data were reported for each indication specific cohort separately.

    Time frame: Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 1, Cycle 1 Days 2, 8, 14

  54. Cmax of Cobimetinib on Cycle 1 Day 1 - Stage 2 Individual Indication Specific Cohorts

    Stage 2 PK data were reported for each indication specific cohort separately.

    Time frame: Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 1, Cycle 1 Days 2, 8, 14

  55. AUC0-24 of Cobimetinib on Cycle 1 Day 1 - Stage 2 All Cohorts

    Stage 2 PK data were reported for each indication specific cohort separately.

    Time frame: Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 1, Cycle 1 Days 2

  56. Tmax of Cobimetinib on Cycle 1 Day 21 - Stage 2 Individual Indication Specific Cohorts

    Stage 2 PK data were reported for each indication specific cohort separately.

    Time frame: Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 21, Cycle 1 Day 22, Cycle 2 Days 1, 15, 21

  57. Cmax of Cobimetinib on Cycle 1 Day 21 - Stage 2 Individual Indication Specific Cohorts

    Stage 2 PK data were reported for each indication specific cohort separately.

    Time frame: Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 21, Cycle 1 Day 22, Cycle 2 Days 1, 15, 21

  58. AUC0-24 of Cobimetinib on Cycle 1 Day 21 - Stage 2 Individual Indication Specific Cohorts

    Stage 2 PK data were reported for each indication specific cohort separately.

    Time frame: Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 21, Cycle 1 Day 22

  59. t1/2 of Cobimetinib on Cycle 1 Day 21 - Stage 2 Individual Indication Specific Cohorts

    Stage 2 PK data were reported for each indication specific cohort separately. Half-life is the time measured for the plasma concentration to decrease by one half.

    Time frame: Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 21, Cycle 1 Day 22

  60. CL/F of Cobimetinib on Cycle 1 Day 21 - Stage 2 Individual Indication Specific Cohorts

    Stage 2 PK data were reported for each indication specific cohort separately. Half-life is the time measured for the plasma concentration to decrease by one half. Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.

    Time frame: Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 21, Cycle 1 Day 22, Cycle 2 Days 1, 15, 21

  61. Accumulation Ratio of Cobimetinib on Cycle 1 Day 21 - Stage 2 Individual Indication Specific Cohorts

    Stage 2 PK data were reported for each indication specific cohort separately. Accumulation ratio was calculated as: AUC0-24 at Cycle 1 Day 21 divided by AUC0-24 at Cycle 1 Day 1.

    Time frame: Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Days 1 and 21, Cycle 1 Days 2 and 22

  62. Tmax of Pictilisib on Cycle 1 Day 1 - Stage 2 Individual Indication Specific Cohorts

    Stage 2 PK data were reported for each indication specific cohort separately.

    Time frame: Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 1, Cycle 1 Days 2, 8, 14

  63. Cmax of Pictilisib on Cycle 1 Day 1 - Stage 2 Individual Indication Specific Cohorts

    Stage 2 PK data were reported for each indication specific cohort separately.

    Time frame: Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 1, Cycle 1 Days 2, 8, 14

  64. AUC0-24 of Pictilisib on Cycle 1 Day 1 - Stage 2 Individual Indication Specific Cohorts

    Stage 2 PK data were reported for each indication specific cohort separately.

    Time frame: Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 1, Cycle 1 Days 2

  65. Tmax of Pictilisib on Cycle 1 Day 21 - Stage 2 Individual Indication Specific Cohorts

    Stage 2 PK data were reported for each indication specific cohort separately.

    Time frame: Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 21, Cycle 1 Day 22, Cycle 2 Days 1, 15, 21

  66. Cmax of Pictilisib on Cycle 1 Day 21 - Stage 2 Individual Indication Specific Cohorts

    Stage 2 PK data were reported for each indication specific cohort separately.

    Time frame: Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 21, Cycle 1 Day 22, Cycle 2 Days 1, 15, 21

  67. AUC0-24 of Pictilisib on Cycle 1 Day 21 - Stage 2 Individual Indication Specific Cohorts

    Stage 2 PK data were reported for each indication specific cohort separately.

    Time frame: Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 21, Cycle 1 Day 22

  68. t1/2 of Pictilisib on Cycle 1 Day 21 - Stage 2 Individual Indication Specific Cohorts

    Stage 2 PK data were reported for each indication specific cohort separately. Half-life is the time measured for the plasma concentration to decrease by one half.

    Time frame: Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 21, Cycle 1 Day 22, Cycle 2 Days 1, 15, 21

  69. CL/F of Pictilisib on Cycle 1 Day 21 - Stage 2 Individual Indication Specific Cohorts

    Stage 2 PK data were reported for each indication specific cohort separately. Half-life is the time measured for the plasma concentration to decrease by one half. Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.

    Time frame: Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 21, Cycle 1 Day 22, Cycle 2 Days 1, 15, 21

  70. Accumulation Ratio of Pictilisib on Cycle 1 Day 21 - Stage 2 Individual Indication Specific Cohorts

    Stage 2 PK data were reported for each indication specific cohort separately. Accumulation ratio was calculated as: AUC0-24 at Cycle 1 Day 21 divided by AUC0-24 at Cycle 1 Day 1.

    Time frame: Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Days 1 and 21, Cycle 1 Days 2 and 22

  71. Tmax of Cobimetinib on Cycle 1 Day 1 - Stage 2A Individual Indication Specific Cohorts

    Stage 2A PK data were reported for each indication specific cohort separately.

    Time frame: Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 1, Cycle 1 Days 2, 8, 15-17

  72. Cmax of Cobimetinib on Cycle 1 Day 1 - Stage 2A Individual Indication Specific Cohorts

    Stage 2A PK data were reported for each indication specific cohort separately.

    Time frame: Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 1, Cycle 1 Days 2, 8, 15-17

  73. AUC0-24 of Cobimetinib on Cycle 1 Day 1 - Stage 2A Individual Indication Specific Cohorts

    Stage 2A PK data were reported for each indication specific cohort separately.

    Time frame: Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 1, Cycle 1 Days 2

  74. Tmax of Cobimetinib on Cycle 1 Day 18 - Stage 2A Individual Indication Specific Cohorts

    Stage 2A PK data were reported for each indication specific cohort separately. As planned, summary statistics were not derived if fewer than 3 participants had available data; however, if the number of participants analyzed = 1, then the observed data of the single participant was reported as median.

    Time frame: Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 18, Cycle 1 Day 19, Cycle 2 Days 1, 15, 21

  75. Cmax of Cobimetinib on Cycle 1 Day 18 - Stage 2A Individual Indication Specific Cohorts

    Stage 2A PK data were reported for each indication specific cohort separately. As planned, summary statistics were not derived if fewer than 3 participants had available data; however, if the number of participants analyzed = 1, then the observed data of the single participant was reported as geometric mean.

    Time frame: Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 18, Cycle 1 Day 19, Cycle 2 Days 1, 15, 21

  76. AUC0-24 of Cobimetinib on Cycle 1 Day 18 - Stage 2A Individual Indication Specific Cohorts

    Stage 2A PK data were reported for each indication specific cohort separately. As planned, summary statistics were not derived if fewer than 3 participants had available data; however, if the number of participants analyzed = 1, then the observed data of the single participant was reported as geometric mean.

    Time frame: Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 18, Cycle 1 Day 19, Cycle 2 Days 1, 15, 21

  77. t1/2 of Cobimetinib on Cycle 1 Day 18 - Stage 2A Individual Indication Specific Cohorts

    Stage 2A PK data were reported for each indication specific cohort separately. Half-life is the time measured for the plasma concentration to decrease by one half. As planned, summary statistics were not derived if fewer than 3 participants had available data; however, if the number of participants analyzed = 1, then the observed data of the single participant was reported as geometric mean.

    Time frame: Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 18, Cycle 1 Day 19, Cycle 2 Days 1, 15, 21

  78. CL/F of Cobimetinib on Cycle 1 Day 18 - Stage 2A Individual Indication Specific Cohorts

    Stage 2A PK data were reported for each indication specific cohort separately. Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood. As planned, summary statistics were not derived if fewer than 3 participants had available data; however, if the number of participants analyzed = 1, then the observed data of the single participant was reported as geometric mean.

    Time frame: Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 18, Cycle 1 Day 19, Cycle 2 Days 1, 15, 21

  79. Accumulation Ratio of Cobimetinib on Cycle 1 Day 18 - Stage 2A Individual Indication Specific Cohorts

    Stage 2A PK data were reported for each indication specific cohort separately. Accumulation ratio was calculated as: AUC0-24 at Cycle 1 Day 21 divided by AUC0-24 at Cycle 1 Day 1. As planned, summary statistics were not derived if fewer than 3 participants had available data; however, if the number of participants analyzed = 1, then the observed data of the single participant was reported as geometric mean.

    Time frame: Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 18, Cycle 1 Day 19, Cycle 2 Days 1, 15, 21

  80. Tmax of Pictilisib on Cycle 1 Day 1 - Stage 2A Individual Indication Specific Cohorts

    Stage 2A PK data were reported for each indication specific cohort separately.

    Time frame: Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 1, Cycle 1 Days 2, 8, 15-17

  81. Cmax of Pictilisib on Cycle 1 Day 1 - Stage 2A Individual Indication Specific Cohorts

    Stage 2A PK data were reported for each indication specific cohort separately.

    Time frame: Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 1, Cycle 1 Days 2, 8, 15-17

  82. AUC0-24 of Pictilisib on Cycle 1 Day 1 - Stage 2A Individual Indication Specific Cohorts

    Stage 2A PK data were reported for each indication specific cohort separately.

    Time frame: Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 1, Cycle 1 Days 2

  83. Tmax of Pictilisib on Cycle 1 Day 18 - Stage 2A Individual Indication Specific Cohorts

    Stage 2A PK data were reported for each indication specific cohort separately. As planned, summary statistics were not derived if fewer than 3 participants had available data; however, if the number of participants analyzed = 1, then the observed data of the single participant was reported as geometric mean.

    Time frame: Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 18, Cycle 1 Day 19, Cycle 2 Days 1, 15, 21

  84. Cmax of Pictilisib on Cycle 1 Day 18 - Stage 2A Individual Indication Specific Cohorts

    Stage 2A PK data were reported for each indication specific cohort separately. As planned, summary statistics were not derived if fewer than 3 participants had available data; however, if the number of participants analyzed = 1, then the observed data of the single participant was reported as geometric mean.

    Time frame: Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 18, Cycle 1 Day 19, Cycle 2 Days 1, 15, 21

  85. AUC0-24 of Pictilisib on Cycle 1 Day 18 - Stage 2A Individual Indication Specific Cohorts

    Stage 2A PK data were reported for each indication specific cohort separately. As planned, summary statistics were not derived if fewer than 3 participants had available data; however, if the number of participants analyzed = 1, then the observed data of the single participant was reported as geometric mean.

    Time frame: Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 18, Cycle 1 Day 19, Cycle 2 Days 1, 15, 21

  86. t1/2 of Pictilisib on Cycle 1 Day 18 - Stage 2A Individual Indication Specific Cohorts

    Stage 2A PK data were reported for each indication specific cohort separately. Half-life is the time measured for the plasma concentration to decrease by one half.

    Time frame: Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 18, Cycle 1 Day 19, Cycle 2 Days 1, 15, 21

  87. CL/F of Pictilisib on Cycle 1 Day 18 - Stage 2A Individual Indication Specific Cohorts

    Stage 2A PK data were reported for each indication specific cohort separately. Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood. As planned, summary statistics were not derived if fewer than 3 participants had available data; however, if the number of participants analyzed = 1, then the observed data of the single participant was reported as geometric mean.

    Time frame: Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 18, Cycle 1 Day 19, Cycle 2 Days 1, 15, 21

  88. Accumulation Ratio of Pictilisib on Cycle 1 Day 18 - Stage 2A Individual Indication Specific Cohorts

    Stage 2A PK data were reported for each indication specific cohort separately. Accumulation ratio was calculated as: AUC0-24 at Cycle 1 Day 21 divided by AUC0-24 at Cycle 1 Day 1. As planned, summary statistics were not derived if fewer than 3 participants had available data; however, if the number of participants analyzed = 1, then the observed data of the single participant was reported as geometric mean.

    Time frame: Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 18, Cycle 1 Day 19, Cycle 2 Days 1, 15, 21

  89. Number of Participants With Best Overall Response - Dose Escalation Stages 1, 1A and 1B

    Tumor response was assessed using Response Evaluation Criteria in Solid Tumors (RECIST). Complete response (CR) = disappearance of all target and non-target lesions. Partial Response (PR) = at least 30 percent (%) decrease in sum of the longest diameter of measured lesions taking as reference the baseline sum of the longest diameter. Progressive disease (PD) = at least 20% increase in the sum of the longest diameter of measured lesions taking as reference the smallest sum of the longest diameter since treatment start or appearance of one or more new lesions. Stable disease (SD) = neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum of the longest diameter since treatment start.

    Time frame: Up to 30 days after last dose (last dose = up to Cycle 15, cycle length = 28 days)

  90. Duration of Objective Response - Dose Escalation Stages 1, 1A and 1B

    Duration of objective response was defined as the time from first occurrence of a documented objective response (CR or PR) until the time of disease progression, as determined by investigator review of tumor assessments using RECIST, or death from any cause during the study (within 30 days after the last dose of study treatment). CR = disappearance of all target and non-target lesions. PR = at least 30 % decrease in sum of the longest diameter of measured lesions taking as reference the baseline sum of the longest diameter. PD = at least 20% increase in the sum of the longest diameter of measured lesions taking as reference the smallest sum of the longest diameter since treatment start or appearance of one or more new lesions.

    Time frame: Up to 30 days after last dose (last dose = up to Cycle 15, cycle length = 28 days)

  91. Progression-Free Survival (PFS) - Dose Escalation Stages 1, 1A and 1B

    PFS was the time from study treatment initiation to the first occurrence of disease progression, as determined by investigator review of tumor assessments using RECIST, or death from any cause during the study (within 30 days after the last dose of study treatment). PD = at least 20% increase in the sum of the longest diameter of measured lesions taking as reference the smallest sum of the longest diameter since treatment start or appearance of one or more new lesions.

    Time frame: Up to 30 days after last dose (last dose = up to Cycle 15, cycle length = 28 days)

07

Results

Posted Dec 30, 2016
Limitations and caveats
The study was terminated prior to the initiation of Stage 2B and as per changes in planned analysis the data for duration of objective response and PFS were not analyzed.

Participant flow

Dose-Escalation Stage 1
Participant flow — Dose-Escalation Stage 1
MilestoneS1 C1: 20 mg Cobimetinib + 80 mg PictilisibS1 C2: 20 mg Cobimetinib + 100 mg PictilisibS1 C3: 40 mg Cobimetinib + 80 mg PictilisibS1 C4: 40 mg Cobimetinib + 100 mg PictilisibS1 C5: 40 mg Cobimetinib + 130 mg PictilisibS1 C6: 60 mg Cobimetinib + 100 mg PictilisibS1 C6A: 80 mg Cobimetinib + 100 mg PictilisibS1A CA: 100 mg Cobimetinib + 130 mg PictilisibS1A CB: 100 mg Cobimetinib + 180 mg PictilisibS1A CC: 125 mg Cobimetinib + 130 mg PictilisibS1A CD: 125 mg Cobimetinib + 180 mg PictilisibS1A CE: 125 mg Cobimetinib + 245 mg PictilisibS1A CF: 150 mg Cobimetinib + 180 mg PictilisibS1A CG: 150 mg Cobimetinib + 245 mg PictilisibS1B CAX: 40 mg Cobimetinib + 130 mg PictilisibS1B CBX: 40 mg Cobimetinib + 180 mg PictilisibS1B CCX: 60 mg Cobimetinib + 130 mg PictilisibS1B CDX: 60 mg Cobimetinib + 180 mg PictilisibS2 Expansion: 40 mg Cobimetinib + 100 mg PictilisibS2A Expansion: 125 mg Cobimetinib + 180 mg Pictilisib
Started4339111040000000000000
Completed00000000000000000000
Not completed4339111040000000000000
Withdrew: Adverse event00020010000000000000
Withdrew: Death10000100000000000000
Withdrew: Physician decision10010120000000000000
Withdrew: Withdrawal by subject01021110000000000000
Withdrew: Disease progression223410700000000000000
Dose-Escalation Stage 1A
Participant flow — Dose-Escalation Stage 1A
MilestoneS1 C1: 20 mg Cobimetinib + 80 mg PictilisibS1 C2: 20 mg Cobimetinib + 100 mg PictilisibS1 C3: 40 mg Cobimetinib + 80 mg PictilisibS1 C4: 40 mg Cobimetinib + 100 mg PictilisibS1 C5: 40 mg Cobimetinib + 130 mg PictilisibS1 C6: 60 mg Cobimetinib + 100 mg PictilisibS1 C6A: 80 mg Cobimetinib + 100 mg PictilisibS1A CA: 100 mg Cobimetinib + 130 mg PictilisibS1A CB: 100 mg Cobimetinib + 180 mg PictilisibS1A CC: 125 mg Cobimetinib + 130 mg PictilisibS1A CD: 125 mg Cobimetinib + 180 mg PictilisibS1A CE: 125 mg Cobimetinib + 245 mg PictilisibS1A CF: 150 mg Cobimetinib + 180 mg PictilisibS1A CG: 150 mg Cobimetinib + 245 mg PictilisibS1B CAX: 40 mg Cobimetinib + 130 mg PictilisibS1B CBX: 40 mg Cobimetinib + 180 mg PictilisibS1B CCX: 60 mg Cobimetinib + 130 mg PictilisibS1B CDX: 60 mg Cobimetinib + 180 mg PictilisibS2 Expansion: 40 mg Cobimetinib + 100 mg PictilisibS2A Expansion: 125 mg Cobimetinib + 180 mg Pictilisib
Started00000003347985000000
Completed00000000000000000000
Not completed00000003347985000000
Withdrew: Adverse event00000000001001000000
Withdrew: Death00000000020110000000
Withdrew: Physician decision00000001000000000000
Withdrew: Withdrawal by subject00000000011110000000
Withdrew: Disease progression00000002315764000000
Dose-Escalation Stage 1B
Participant flow — Dose-Escalation Stage 1B
MilestoneS1 C1: 20 mg Cobimetinib + 80 mg PictilisibS1 C2: 20 mg Cobimetinib + 100 mg PictilisibS1 C3: 40 mg Cobimetinib + 80 mg PictilisibS1 C4: 40 mg Cobimetinib + 100 mg PictilisibS1 C5: 40 mg Cobimetinib + 130 mg PictilisibS1 C6: 60 mg Cobimetinib + 100 mg PictilisibS1 C6A: 80 mg Cobimetinib + 100 mg PictilisibS1A CA: 100 mg Cobimetinib + 130 mg PictilisibS1A CB: 100 mg Cobimetinib + 180 mg PictilisibS1A CC: 125 mg Cobimetinib + 130 mg PictilisibS1A CD: 125 mg Cobimetinib + 180 mg PictilisibS1A CE: 125 mg Cobimetinib + 245 mg PictilisibS1A CF: 150 mg Cobimetinib + 180 mg PictilisibS1A CG: 150 mg Cobimetinib + 245 mg PictilisibS1B CAX: 40 mg Cobimetinib + 130 mg PictilisibS1B CBX: 40 mg Cobimetinib + 180 mg PictilisibS1B CCX: 60 mg Cobimetinib + 130 mg PictilisibS1B CDX: 60 mg Cobimetinib + 180 mg PictilisibS2 Expansion: 40 mg Cobimetinib + 100 mg PictilisibS2A Expansion: 125 mg Cobimetinib + 180 mg Pictilisib
Started00000000000000433500
Completed00000000000000000000
Not completed00000000000000433500
Withdrew: Physician decision00000000000000000200
Withdrew: Disease progression00000000000000433300
Expansion Stage 2
Participant flow — Expansion Stage 2
MilestoneS1 C1: 20 mg Cobimetinib + 80 mg PictilisibS1 C2: 20 mg Cobimetinib + 100 mg PictilisibS1 C3: 40 mg Cobimetinib + 80 mg PictilisibS1 C4: 40 mg Cobimetinib + 100 mg PictilisibS1 C5: 40 mg Cobimetinib + 130 mg PictilisibS1 C6: 60 mg Cobimetinib + 100 mg PictilisibS1 C6A: 80 mg Cobimetinib + 100 mg PictilisibS1A CA: 100 mg Cobimetinib + 130 mg PictilisibS1A CB: 100 mg Cobimetinib + 180 mg PictilisibS1A CC: 125 mg Cobimetinib + 130 mg PictilisibS1A CD: 125 mg Cobimetinib + 180 mg PictilisibS1A CE: 125 mg Cobimetinib + 245 mg PictilisibS1A CF: 150 mg Cobimetinib + 180 mg PictilisibS1A CG: 150 mg Cobimetinib + 245 mg PictilisibS1B CAX: 40 mg Cobimetinib + 130 mg PictilisibS1B CBX: 40 mg Cobimetinib + 180 mg PictilisibS1B CCX: 60 mg Cobimetinib + 130 mg PictilisibS1B CDX: 60 mg Cobimetinib + 180 mg PictilisibS2 Expansion: 40 mg Cobimetinib + 100 mg PictilisibS2A Expansion: 125 mg Cobimetinib + 180 mg Pictilisib
Started000000000000000000350
Completed00000000000000000000
Not completed000000000000000000350
Withdrew: Adverse event00000000000000000030
Withdrew: Death00000000000000000020
Withdrew: Physician decision00000000000000000010
Withdrew: Withdrawal by subject00000000000000000010
Withdrew: Disease progression000000000000000000280
Expansion Stage 2A
Participant flow — Expansion Stage 2A
MilestoneS1 C1: 20 mg Cobimetinib + 80 mg PictilisibS1 C2: 20 mg Cobimetinib + 100 mg PictilisibS1 C3: 40 mg Cobimetinib + 80 mg PictilisibS1 C4: 40 mg Cobimetinib + 100 mg PictilisibS1 C5: 40 mg Cobimetinib + 130 mg PictilisibS1 C6: 60 mg Cobimetinib + 100 mg PictilisibS1 C6A: 80 mg Cobimetinib + 100 mg PictilisibS1A CA: 100 mg Cobimetinib + 130 mg PictilisibS1A CB: 100 mg Cobimetinib + 180 mg PictilisibS1A CC: 125 mg Cobimetinib + 130 mg PictilisibS1A CD: 125 mg Cobimetinib + 180 mg PictilisibS1A CE: 125 mg Cobimetinib + 245 mg PictilisibS1A CF: 150 mg Cobimetinib + 180 mg PictilisibS1A CG: 150 mg Cobimetinib + 245 mg PictilisibS1B CAX: 40 mg Cobimetinib + 130 mg PictilisibS1B CBX: 40 mg Cobimetinib + 180 mg PictilisibS1B CCX: 60 mg Cobimetinib + 130 mg PictilisibS1B CDX: 60 mg Cobimetinib + 180 mg PictilisibS2 Expansion: 40 mg Cobimetinib + 100 mg PictilisibS2A Expansion: 125 mg Cobimetinib + 180 mg Pictilisib
Started000000000000000000045
Completed00000000000000000000
Not completed000000000000000000045
Withdrew: Adverse event00000000000000000008
Withdrew: Physician decision00000000000000000002
Withdrew: Withdrawal by subject00000000000000000004
Withdrew: Disease progression000000000000000000031

Outcome measures

PrimaryNumber of Participants With Dose-Limiting Toxicities (DLTs) During Dose Escalation Stages 1, 1A and 1B

DLT was defined as 1 of the following toxicities considered treatment related by Investigator: Grade ≥3 non-hematologic, non-hepatic organ toxicity, excluding the following: Grade 3 nausea, vomiting, or diarrhea that resolved to Grade ≤1 within 7 days, Grade 3 rash or Grade ≥3 fatigue that resolved to Grade ≤2 within 7 days, Grade ≥3 hyperglycemia or lipid profile results that occurred during non-fasting conditions, Grade 3 or 4 elevation of serum creatine phosphokinase levels or Grade 3 non clinically significant (as assessed by Investigator) laboratory abnormality that was asymptomatic; Grade ≥3 febrile neutropenia; Grade ≥4 neutropenia (absolute neutrophil count \<500/microliter) lasting \>5 days; Grade ≥4 thrombocytopenia lasting \>48 hours; Grade ≥4 anemia; Grade ≥3 total bilirubin, hepatic transaminase, alkaline phosphatase, lasting \>72 hours; Grade ≥2 diffusion capacity of the lung for carbon monoxide concomitant with an absolute decrease of ≥20 percentage points from baseline.

Time frame:
Cohorts 1-3: Day 1 to Day 35, All other cohorts: Day 1 to Day 28
Reported as:
Number · participants
Number of Participants With Dose-Limiting Toxicities (DLTs) During Dose Escalation Stages 1, 1A and 1B
participantsS1 C1: 20 mg Cobimetinib + 80 mg PictilisibS1 C2: 20 mg Cobimetinib + 100 mg PictilisibS1 C3: 40 mg Cobimetinib + 80 mg PictilisibS1 C4: 40 mg Cobimetinib + 100 mg PictilisibS1 C5: 40 mg Cobimetinib + 130 mg PictilisibS1 C6: 60 mg Cobimetinib + 100 mg PictilisibS1 C6A: 80 mg Cobimetinib + 100 mg PictilisibS1A CA: 100 mg Cobimetinib + 130 mg PictilisibS1A CB: 100 mg Cobimetinib + 180 mg PictilisibS1A CC: 125 mg Cobimetinib + 130 mg PictilisibS1A CD: 125 mg Cobimetinib + 180 mg PictilisibS1A CE: 125 mg Cobimetinib + 245 mg PictilisibS1A CF: 150 mg Cobimetinib + 180 mg PictilisibS1A CG: 150 mg Cobimetinib + 245 mg PictilisibS1B CAX: 40 mg Cobimetinib + 130 mg PictilisibS1B CBX: 40 mg Cobimetinib + 180 mg PictilisibS1B CCX: 60 mg Cobimetinib + 130 mg PictilisibS1B CDX: 60 mg Cobimetinib + 180 mg Pictilisib
Number of Participants With Dose-Limiting Toxicities (DLTs) During Dose Escalation Stages 1, 1A and 1B000110000000120001
PrimaryMaximum Tolerated Combination Doses of Cobimetinib and Pictilisib During Dose-Escalation Stages 1, 1A and 1B

MTD was determined (by Investigator) based on the DLTs, as well as adverse events (AEs) in dose-escalation Stages 1, 1A, and 1B that did not meet protocol-defined DLT criteria but indicated intolerability of a given dose combination. Separate combination MTDs were determined for each dose-escalation stage. DLT was defined as 1 of the following toxicities considered treatment related by Investigator: Grade ≥3 non-hematologic, non-hepatic organ toxicity; Grade ≥3 febrile neutropenia; Grade ≥4 neutropenia (absolute neutrophil count \<500/microliter) lasting \>5 days; Grade ≥4 thrombocytopenia lasting \>48 hours; Grade ≥4 anemia; Grade ≥3 total bilirubin, hepatic transaminase, alkaline phosphatase, lasting \>72 hours; Grade ≥2 diffusion capacity of the lung for carbon monoxide concomitant with an absolute decrease of ≥20 percentage points from baseline.

Time frame:
Cohorts 1-3: Day 1 to Day 35, All other cohorts: Day 1 to Day 28
Reported as:
Number · mg
Maximum Tolerated Combination Doses of Cobimetinib and Pictilisib During Dose-Escalation Stages 1, 1A and 1B
mgAll Participants - Stages 1, 1A, 1B
Stage 1: Cobimetinib (n = 44)40
Stage 1: Pictilisib (n = 44)100
Stage 1A: Cobimetinib (n = 34)125
Stage 1A: Pictilisib (n = 34)180
Stage 1B: Cobimetinib (n = 20)NA
Stage 1B: Pictilisib (n = 20)NA
PrimaryTime of Maximum Concentration (Tmax) of Cobimetinib on Day 3 - Stage 1, Cohorts 1-3
Time frame:
0-4 hours pre-cobimetinib (Pr-C) dose, 0.5, 2, 4, 6 hours post-cobimetinib (Po-C) dose on Day 3, Day 4
Reported as:
Median · hours
Time of Maximum Concentration (Tmax) of Cobimetinib on Day 3 - Stage 1, Cohorts 1-3
hoursS1 C1: 20 mg Cobimetinib + 80 mg PictilisibS1 C2: 20 mg Cobimetinib + 100 mg PictilisibS1 C3: 40 mg Cobimetinib + 80 mg Pictilisib
Time of Maximum Concentration (Tmax) of Cobimetinib on Day 3 - Stage 1, Cohorts 1-34.00 (2.0 to 4.0)4.00 (4.0 to 4.0)2.00 (2.0 to 2.0)
PrimaryMaximum Plasma Concentration (Cmax) of Cobimetinib on Day 3 - Stage 1, Cohorts 1-3
Time frame:
0-4 hours Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Day 3, Day 4
Reported as:
Geometric mean · nanograms per milliliter (ng/mL)
Maximum Plasma Concentration (Cmax) of Cobimetinib on Day 3 - Stage 1, Cohorts 1-3
nanograms per milliliter (ng/mL)S1 C1: 20 mg Cobimetinib + 80 mg PictilisibS1 C2: 20 mg Cobimetinib + 100 mg PictilisibS1 C3: 40 mg Cobimetinib + 80 mg Pictilisib
Maximum Plasma Concentration (Cmax) of Cobimetinib on Day 3 - Stage 1, Cohorts 1-327.6 ± 9516.6 ± 7897.0 ± 63
PrimaryArea Under the Concentration-Time Curve From Time 0 to 24 Hours Post-Dose (AUC0-24) of Cobimetinib on Day 3 - Stage 1, Cohorts 1-3
Time frame:
0-4 hours Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Day 3, Day 4
Reported as:
Geometric mean · nonograms*hour per milliliter (ng*h/mL)
Area Under the Concentration-Time Curve From Time 0 to 24 Hours Post-Dose (AUC0-24) of Cobimetinib on Day 3 - Stage 1, Cohorts 1-3
nonograms*hour per milliliter (ng*h/mL)S1 C1: 20 mg Cobimetinib + 80 mg PictilisibS1 C2: 20 mg Cobimetinib + 100 mg PictilisibS1 C3: 40 mg Cobimetinib + 80 mg Pictilisib
Area Under the Concentration-Time Curve From Time 0 to 24 Hours Post-Dose (AUC0-24) of Cobimetinib on Day 3 - Stage 1, Cohorts 1-3392 ± 88279 ± 751190 ± 53
PrimaryTmax of Pictilisib on Day 1 - Stage 1, Cohorts 1-3
Time frame:
0-4 hours pre-pictilisib (Pr-P) dose, 0.5, 2, 4, 6 hours post-pictilisib (Po-P) dose on Day 1, Day 2, 0-4 hours Pr-C dose on Day 3
Reported as:
Median · hours
Tmax of Pictilisib on Day 1 - Stage 1, Cohorts 1-3
hoursS1 C1: 20 mg Cobimetinib + 80 mg PictilisibS1 C2: 20 mg Cobimetinib + 100 mg PictilisibS1 C3: 40 mg Cobimetinib + 80 mg Pictilisib
Tmax of Pictilisib on Day 1 - Stage 1, Cohorts 1-33.00 (2.0 to 24.0)4.00 (2.0 to 4.0)2.00 (2.0 to 2.0)
PrimaryCmax of Pictilisib on Day 1 - Stage 1, Cohorts 1-3
Time frame:
0-4 hours Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Day 1, Day 2, 0-4 hours Pr-C dose on Day 3
Reported as:
Geometric mean · ng/mL
Cmax of Pictilisib on Day 1 - Stage 1, Cohorts 1-3
ng/mLS1 C1: 20 mg Cobimetinib + 80 mg PictilisibS1 C2: 20 mg Cobimetinib + 100 mg PictilisibS1 C3: 40 mg Cobimetinib + 80 mg Pictilisib
Cmax of Pictilisib on Day 1 - Stage 1, Cohorts 1-3162 ± 37185 ± 27280 ± 41
PrimaryAUC0-24 of Pictilisib on Day 1 - Stage 1, Cohorts 1-3
Time frame:
0-4 hours Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Day 1, Day 2, 0-4 hours Pr-C dose on Day 3
Reported as:
Geometric mean · ng*h/mL
AUC0-24 of Pictilisib on Day 1 - Stage 1, Cohorts 1-3
ng*h/mLS1 C1: 20 mg Cobimetinib + 80 mg PictilisibS1 C2: 20 mg Cobimetinib + 100 mg PictilisibS1 C3: 40 mg Cobimetinib + 80 mg Pictilisib
AUC0-24 of Pictilisib on Day 1 - Stage 1, Cohorts 1-31680 ± 161950 ± 502680 ± 83
SecondaryTmax of Cobimetinib on Cycle 1 Day 1 (Cycle 1 Day 8 for Cohorts 1-3) - Stage 1 All Cohorts
Time frame:
Cohorts 1-3: Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 8, Cycle 1 Days 9, 15, 21; Cohorts 4-6A: Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 1, Cycle 1 Day 2, 8, 14
Reported as:
Median · hours
Tmax of Cobimetinib on Cycle 1 Day 1 (Cycle 1 Day 8 for Cohorts 1-3) - Stage 1 All Cohorts
hoursS1 C1: 20 mg Cobimetinib + 80 mg PictilisibS1 C2: 20 mg Cobimetinib + 100 mg PictilisibS1 C3: 40 mg Cobimetinib + 80 mg PictilisibS1 C4: 40 mg Cobimetinib + 100 mg PictilisibS1 C5: 40 mg Cobimetinib + 130 mg PictilisibS1 C6: 60 mg Cobimetinib + 100 mg PictilisibS1 C6A: 80 mg Cobimetinib + 100 mg Pictilisib
Tmax of Cobimetinib on Cycle 1 Day 1 (Cycle 1 Day 8 for Cohorts 1-3) - Stage 1 All Cohorts4.00 (2.0 to 4.0)4.00 (2.0 to 24)2.00 (2.0 to 2.0)2.00 (2.0 to 4.0)2.00 (2.0 to 2.0)4.00 (2.0 to 4.0)3.00 (2.0 to 4.0)
SecondaryCmax of Cobimetinib on Cycle 1 Day 1 (Cycle 1 Day 8 for Cohorts 1-3) - Stage 1 All Cohorts
Time frame:
Cohorts 1-3: Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 8, Cycle 1 Days 9, 15, 21; Cohorts 4-6A: Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 1, Cycle 1 Day 2, 8, 14
Reported as:
Geometric mean · ng/mL
Cmax of Cobimetinib on Cycle 1 Day 1 (Cycle 1 Day 8 for Cohorts 1-3) - Stage 1 All Cohorts
ng/mLS1 C1: 20 mg Cobimetinib + 80 mg PictilisibS1 C2: 20 mg Cobimetinib + 100 mg PictilisibS1 C3: 40 mg Cobimetinib + 80 mg PictilisibS1 C4: 40 mg Cobimetinib + 100 mg PictilisibS1 C5: 40 mg Cobimetinib + 130 mg PictilisibS1 C6: 60 mg Cobimetinib + 100 mg PictilisibS1 C6A: 80 mg Cobimetinib + 100 mg Pictilisib
Cmax of Cobimetinib on Cycle 1 Day 1 (Cycle 1 Day 8 for Cohorts 1-3) - Stage 1 All Cohorts20.2 ± 10017.7 ± 6287.4 ± 73101 ± 6361.0 ± 45131 ± 66138 ± 61
SecondaryAUC0-24 of Cobimetinib on Cycle 1 Day 1 (Cycle 1 Day 8 for Cohorts 1-3) - Stage 1 All Cohorts
Time frame:
Cohorts 1-3: Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 8, Cycle 1 Days 9; Cohorts 4-6A: Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 1, Cycle 1 Day 2
Reported as:
Geometric mean · ng*h/mL
AUC0-24 of Cobimetinib on Cycle 1 Day 1 (Cycle 1 Day 8 for Cohorts 1-3) - Stage 1 All Cohorts
ng*h/mLS1 C1: 20 mg Cobimetinib + 80 mg PictilisibS1 C2: 20 mg Cobimetinib + 100 mg PictilisibS1 C3: 40 mg Cobimetinib + 80 mg PictilisibS1 C4: 40 mg Cobimetinib + 100 mg PictilisibS1 C5: 40 mg Cobimetinib + 130 mg PictilisibS1 C6: 60 mg Cobimetinib + 100 mg PictilisibS1 C6A: 80 mg Cobimetinib + 100 mg Pictilisib
AUC0-24 of Cobimetinib on Cycle 1 Day 1 (Cycle 1 Day 8 for Cohorts 1-3) - Stage 1 All Cohorts299 ± 62311 ± 531320 ± 56.61300 ± 61957 ± 422050 ± 711790 ± 56
SecondaryTmax of Cobimetinib on Cycle 1 Day 21 (Cycle 1 Day 28 for Cohorts 1-3) - Stage 1 All Cohorts
Time frame:
Cohorts 1-3: Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 28, Cycle 1 Day 29, Cycle 2 Days 1, 15, 21; Cohorts 4-6A: Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 21, Cycle 1 Day 22, Cycle 2 Days 1, 15, 21
Reported as:
Median · hours
Tmax of Cobimetinib on Cycle 1 Day 21 (Cycle 1 Day 28 for Cohorts 1-3) - Stage 1 All Cohorts
hoursS1 C1: 20 mg Cobimetinib + 80 mg PictilisibS1 C2: 20 mg Cobimetinib + 100 mg PictilisibS1 C3: 40 mg Cobimetinib + 80 mg PictilisibS1 C4: 40 mg Cobimetinib + 100 mg PictilisibS1 C5: 40 mg Cobimetinib + 130 mg PictilisibS1 C6: 60 mg Cobimetinib + 100 mg PictilisibS1 C6A: 80 mg Cobimetinib + 100 mg Pictilisib
Tmax of Cobimetinib on Cycle 1 Day 21 (Cycle 1 Day 28 for Cohorts 1-3) - Stage 1 All Cohorts6.00 (2.0 to 6.0)4.00 (4.0 to 6.0)2.00 (2.0 to 24)2.00 (2.0 to 4.0)4.00 (2.0 to 24)3.0 (2.0 to 24)4 (NA to NA)
SecondaryCmax of Cobimetinib on Cycle 1 Day 21 (Cycle 1 Day 28 for Cohorts 1-3) - Stage 1 All Cohorts
Time frame:
Cohorts 1-3: Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 28, Cycle 1 Day 29, Cycle 2 Days 1, 15, 21; Cohorts 4-6A: Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 21, Cycle 1 Day 22, Cycle 2 Days 1, 15, 21
Reported as:
Geometric mean · ng/mL
Cmax of Cobimetinib on Cycle 1 Day 21 (Cycle 1 Day 28 for Cohorts 1-3) - Stage 1 All Cohorts
ng/mLS1 C1: 20 mg Cobimetinib + 80 mg PictilisibS1 C2: 20 mg Cobimetinib + 100 mg PictilisibS1 C3: 40 mg Cobimetinib + 80 mg PictilisibS1 C4: 40 mg Cobimetinib + 100 mg PictilisibS1 C5: 40 mg Cobimetinib + 130 mg PictilisibS1 C6: 60 mg Cobimetinib + 100 mg PictilisibS1 C6A: 80 mg Cobimetinib + 100 mg Pictilisib
Cmax of Cobimetinib on Cycle 1 Day 21 (Cycle 1 Day 28 for Cohorts 1-3) - Stage 1 All Cohorts37.1 ± 5.652.2 ± 57228 ± 120167 ± 56138 ± 63245 ± 7987.4 ± NA
SecondaryAUC0-24 of Cobimetinib on Cycle 1 Day 21 (Cycle 1 Day 28 for Cohorts 1-3) - Stage 1 All Cohorts
Time frame:
Cohorts 1-3: Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 28, Cycle 1 Day 29; Cohorts 4-6A: Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 21, Cycle 1 Day 22
Reported as:
Geometric mean · ng*h/mL
AUC0-24 of Cobimetinib on Cycle 1 Day 21 (Cycle 1 Day 28 for Cohorts 1-3) - Stage 1 All Cohorts
ng*h/mLS1 C1: 20 mg Cobimetinib + 80 mg PictilisibS1 C2: 20 mg Cobimetinib + 100 mg PictilisibS1 C3: 40 mg Cobimetinib + 80 mg PictilisibS1 C4: 40 mg Cobimetinib + 100 mg PictilisibS1 C5: 40 mg Cobimetinib + 130 mg PictilisibS1 C6: 60 mg Cobimetinib + 100 mg PictilisibS1 C6A: 80 mg Cobimetinib + 100 mg Pictilisib
AUC0-24 of Cobimetinib on Cycle 1 Day 21 (Cycle 1 Day 28 for Cohorts 1-3) - Stage 1 All Cohorts749 ± 1.4900 ± 704130 ± 942410 ± 662460 ± 574050 ± 1101120 ± NA
SecondaryTerminal Half-life (t1/2) of Cobimetinib on Cycle 1 Day 21 (Cycle 1 Day 28 for Cohorts 1-3) - Stage 1 All Cohorts

Half-life is the time measured for the plasma concentration to decrease by one half.

Time frame:
Cohorts 1-3: Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 28, Cycle 1 Day 29, Cycle 2 Days 1, 15, 21; Cohorts 4-6A: Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 21, Cycle 1 Day 22, Cycle 2 Days 1, 15, 21
Reported as:
Geometric mean · hours
Terminal Half-life (t1/2) of Cobimetinib on Cycle 1 Day 21 (Cycle 1 Day 28 for Cohorts 1-3) - Stage 1 All Cohorts
hoursS1 C1: 20 mg Cobimetinib + 80 mg PictilisibS1 C2: 20 mg Cobimetinib + 100 mg PictilisibS1 C3: 40 mg Cobimetinib + 80 mg PictilisibS1 C4: 40 mg Cobimetinib + 100 mg PictilisibS1 C5: 40 mg Cobimetinib + 130 mg PictilisibS1 C6: 60 mg Cobimetinib + 100 mg PictilisibS1 C6A: 80 mg Cobimetinib + 100 mg Pictilisib
Terminal Half-life (t1/2) of Cobimetinib on Cycle 1 Day 21 (Cycle 1 Day 28 for Cohorts 1-3) - Stage 1 All Cohorts49.3 (41 to 60)37.9 (32 to 43)31.7 (22 to 48)34.1 (32 to 37)43.2 (34 to 56)45.7 (41 to 56)40.5 (NA to NA)
SecondaryApparent Clearance (CL/F) of Cobimetinib on Cycle 1 Day 21 (Cycle 1 Day 28 for Cohorts 1-3) - Stage 1 All Cohorts

Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.

Time frame:
Cohorts 1-3: Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 28, Cycle 1 Day 29, Cycle 2 Days 1, 15, 21; Cohorts 4-6A: Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 21, Cycle 1 Day 22, Cycle 2 Days 1, 15, 21
Reported as:
Geometric mean · Liters per hour (L/hr)
Apparent Clearance (CL/F) of Cobimetinib on Cycle 1 Day 21 (Cycle 1 Day 28 for Cohorts 1-3) - Stage 1 All Cohorts
Liters per hour (L/hr)S1 C1: 20 mg Cobimetinib + 80 mg PictilisibS1 C2: 20 mg Cobimetinib + 100 mg PictilisibS1 C3: 40 mg Cobimetinib + 80 mg PictilisibS1 C4: 40 mg Cobimetinib + 100 mg PictilisibS1 C5: 40 mg Cobimetinib + 130 mg PictilisibS1 C6: 60 mg Cobimetinib + 100 mg PictilisibS1 C6A: 80 mg Cobimetinib + 100 mg Pictilisib
Apparent Clearance (CL/F) of Cobimetinib on Cycle 1 Day 21 (Cycle 1 Day 28 for Cohorts 1-3) - Stage 1 All Cohorts26.7 ± 1.422.2 ± 709.67 ± 9416.6 ± 6616.2 ± 6114.8 ± 11053.6 ± NA
SecondaryAccumulation Ratio of Cobimetinib on Cycle 1 Day 21 (Cycle 1 Day 28 for Cohorts 1-3) - Stage 1 All Cohorts

Accumulation ratio was calculated as: AUC0-24 at Cycle 1 Day 21 (Cycle 1 Day 28 for Cohorts 1-3) divided by AUC0-24 at Cycle 1 Day 1 (Cycle 1 Day 8 for Cohorts 1-3).

Time frame:
Cohorts 1-3: Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Days 8 and 28, Cycle 1 Days 9, 29; Cohorts 4-6A: Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Days 1 and 21, Cycle 1 Days 2, 22
Reported as:
Geometric mean · ratio
Accumulation Ratio of Cobimetinib on Cycle 1 Day 21 (Cycle 1 Day 28 for Cohorts 1-3) - Stage 1 All Cohorts
ratioS1 C1: 20 mg Cobimetinib + 80 mg PictilisibS1 C2: 20 mg Cobimetinib + 100 mg PictilisibS1 C3: 40 mg Cobimetinib + 80 mg PictilisibS1 C4: 40 mg Cobimetinib + 100 mg PictilisibS1 C5: 40 mg Cobimetinib + 130 mg PictilisibS1 C6: 60 mg Cobimetinib + 100 mg PictilisibS1 C6A: 80 mg Cobimetinib + 100 mg Pictilisib
Accumulation Ratio of Cobimetinib on Cycle 1 Day 21 (Cycle 1 Day 28 for Cohorts 1-3) - Stage 1 All Cohorts2.51 ± 632.89 ± 433.14 ± 732.03 ± 362.90 ± 732.83 ± 541.77 ± NA
SecondaryTmax of Pictilisib on Cycle 1 Day 1 (Cycle 1 Day 8 for Cohorts 1-3) - Stage 1 All Cohorts
Time frame:
Cohorts 1-3: Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 8, Cycle 1 Day 9, 15, 21; Cohorts 4-6A: Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 1, Cycle 1 Day 2, 8, 14
Reported as:
Median · hours
Tmax of Pictilisib on Cycle 1 Day 1 (Cycle 1 Day 8 for Cohorts 1-3) - Stage 1 All Cohorts
hoursS1 C1: 20 mg Cobimetinib + 80 mg PictilisibS1 C2: 20 mg Cobimetinib + 100 mg PictilisibS1 C3: 40 mg Cobimetinib + 80 mg PictilisibS1 C4: 40 mg Cobimetinib + 100 mg PictilisibS1 C5: 40 mg Cobimetinib + 130 mg PictilisibS1 C6: 60 mg Cobimetinib + 100 mg PictilisibS1 C6A: 80 mg Cobimetinib + 100 mg Pictilisib
Tmax of Pictilisib on Cycle 1 Day 1 (Cycle 1 Day 8 for Cohorts 1-3) - Stage 1 All Cohorts2.00 (2.0 to 4.0)2.00 (2.0 to 4.0)2.00 (2.0 to 2.0)2.00 (0.5 to 4.0)2.00 (2.0 to 4.0)2.00 (0.5 to 4.0)2.00 (2.0 to 4.0)
SecondaryCmax of Pictilisib on Cycle 1 Day 1 (Cycle 1 Day 8 for Cohorts 1-3) - Stage 1 All Cohorts
Time frame:
Cohorts 1-3: Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 8, Cycle 1 Day 9, 15, 21; Cohorts 4-6A: Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 1, Cycle 1 Day 2, 8, 14
Reported as:
Geometric mean · ng/mL
Cmax of Pictilisib on Cycle 1 Day 1 (Cycle 1 Day 8 for Cohorts 1-3) - Stage 1 All Cohorts
ng/mLS1 C1: 20 mg Cobimetinib + 80 mg PictilisibS1 C2: 20 mg Cobimetinib + 100 mg PictilisibS1 C3: 40 mg Cobimetinib + 80 mg PictilisibS1 C4: 40 mg Cobimetinib + 100 mg PictilisibS1 C5: 40 mg Cobimetinib + 130 mg PictilisibS1 C6: 60 mg Cobimetinib + 100 mg PictilisibS1 C6A: 80 mg Cobimetinib + 100 mg Pictilisib
Cmax of Pictilisib on Cycle 1 Day 1 (Cycle 1 Day 8 for Cohorts 1-3) - Stage 1 All Cohorts196 ± 20193 ± 16329 ± 26390 ± 60302 ± 34272 ± 54355 ± 83
SecondaryAUC0-24 of Pictilisib on Cycle 1 Day 1 (Cycle 1 Day 8 for Cohorts 1-3) - Stage 1 All Cohorts
Time frame:
Cohorts 1-3: Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 8, Cycle 1 Day 9; Cohorts 4-6A: Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 1, Cycle 1 Day 2
Reported as:
Geometric mean · ng*h/mL
AUC0-24 of Pictilisib on Cycle 1 Day 1 (Cycle 1 Day 8 for Cohorts 1-3) - Stage 1 All Cohorts
ng*h/mLS1 C1: 20 mg Cobimetinib + 80 mg PictilisibS1 C2: 20 mg Cobimetinib + 100 mg PictilisibS1 C3: 40 mg Cobimetinib + 80 mg PictilisibS1 C4: 40 mg Cobimetinib + 100 mg PictilisibS1 C5: 40 mg Cobimetinib + 130 mg PictilisibS1 C6: 60 mg Cobimetinib + 100 mg PictilisibS1 C6A: 80 mg Cobimetinib + 100 mg Pictilisib
AUC0-24 of Pictilisib on Cycle 1 Day 1 (Cycle 1 Day 8 for Cohorts 1-3) - Stage 1 All Cohorts1660 ± 282150 ± 432600 ± 283360 ± 432770 ± 432870 ± 483240 ± 68
SecondaryTmax of Pictilisib on Cycle 1 Day 21 (Cycle 1 Day 28 for Cohorts 1-3) - Stage 1 All Cohorts
Time frame:
Cohorts 1-3: Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 28, Cycle 1 Day 29, Cycle 2 Days 1, 15, 21; Cohorts 4-6A: Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 21, Cycle 1 Day 22, Cycle 2 Days 1, 15, 21
Reported as:
Median · hours
Tmax of Pictilisib on Cycle 1 Day 21 (Cycle 1 Day 28 for Cohorts 1-3) - Stage 1 All Cohorts
hoursS1 C1: 20 mg Cobimetinib + 80 mg PictilisibS1 C2: 20 mg Cobimetinib + 100 mg PictilisibS1 C3: 40 mg Cobimetinib + 80 mg PictilisibS1 C4: 40 mg Cobimetinib + 100 mg PictilisibS1 C5: 40 mg Cobimetinib + 130 mg PictilisibS1 C6: 60 mg Cobimetinib + 100 mg PictilisibS1 C6A: 80 mg Cobimetinib + 100 mg Pictilisib
Tmax of Pictilisib on Cycle 1 Day 21 (Cycle 1 Day 28 for Cohorts 1-3) - Stage 1 All Cohorts2.00 (2.0 to 6.0)2.00 (2.0 to 2.0)2.00 (2.0 to 4.0)2.00 (0.5 to 4.0)2.00 (2.0 to 6.0)2.00 (2.0 to 24)2.00 (NA to NA)
SecondaryCmax of Pictilisib on Cycle 1 Day 21 (Cycle 1 Day 28 for Cohorts 1-3) - Stage 1 All Cohorts
Time frame:
Cohorts 1-3: Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 28, Cycle 1 Day 29, Cycle 2 Days 1, 15, 21; Cohorts 4-6A: Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 21, Cycle 1 Day 22, Cycle 2 Days 1, 15, 21
Reported as:
Geometric mean · ng/mL
Cmax of Pictilisib on Cycle 1 Day 21 (Cycle 1 Day 28 for Cohorts 1-3) - Stage 1 All Cohorts
ng/mLS1 C1: 20 mg Cobimetinib + 80 mg PictilisibS1 C2: 20 mg Cobimetinib + 100 mg PictilisibS1 C3: 40 mg Cobimetinib + 80 mg PictilisibS1 C4: 40 mg Cobimetinib + 100 mg PictilisibS1 C5: 40 mg Cobimetinib + 130 mg PictilisibS1 C6: 60 mg Cobimetinib + 100 mg PictilisibS1 C6A: 80 mg Cobimetinib + 100 mg Pictilisib
Cmax of Pictilisib on Cycle 1 Day 21 (Cycle 1 Day 28 for Cohorts 1-3) - Stage 1 All Cohorts198 ± 38278 ± 100459 ± 20409 ± 49374 ± 69396 ± 48441 ± NA
SecondaryAUC0-24 of Pictilisib on Cycle 1 Day 21 (Cycle 1 Day 28 for Cohorts 1-3) - Stage 1 All Cohorts
Time frame:
Cohorts 1-3: Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 28, Cycle 1 Day 29; Cohorts 4-6A: Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 21, Cycle 1 Day 22
Reported as:
Geometric mean · ng*h/mL
AUC0-24 of Pictilisib on Cycle 1 Day 21 (Cycle 1 Day 28 for Cohorts 1-3) - Stage 1 All Cohorts
ng*h/mLS1 C1: 20 mg Cobimetinib + 80 mg PictilisibS1 C2: 20 mg Cobimetinib + 100 mg PictilisibS1 C3: 40 mg Cobimetinib + 80 mg PictilisibS1 C4: 40 mg Cobimetinib + 100 mg PictilisibS1 C5: 40 mg Cobimetinib + 130 mg PictilisibS1 C6: 60 mg Cobimetinib + 100 mg PictilisibS1 C6A: 80 mg Cobimetinib + 100 mg Pictilisib
AUC0-24 of Pictilisib on Cycle 1 Day 21 (Cycle 1 Day 28 for Cohorts 1-3) - Stage 1 All Cohorts2500 ± 212930 ± 1505500 ± 343890 ± 634320 ± 584510 ± 404070 ± NA
Secondaryt1/2 of Pictilisib on Cycle 1 Day 21 (Cycle 1 Day 28 for Cohorts 1-3) - Stage 1 All Cohorts

Half-life is the time measured for the plasma concentration to decrease by one half. As planned, summary statistics were not derived if fewer than 3 participants had available data; however, if the number of participants analyzed = 1, then the observed data of the single participant was reported as geometric mean.

Time frame:
Cohorts 1-3: Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 28, Cycle 1 Day 29, Cycle 2 Days 1, 15, 21; Cohorts 4-6A: Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 21, Cycle 1 Day 22, Cycle 2 Days 1, 15, 21
Reported as:
Geometric mean · hours
t1/2 of Pictilisib on Cycle 1 Day 21 (Cycle 1 Day 28 for Cohorts 1-3) - Stage 1 All Cohorts
hoursS1 C1: 20 mg Cobimetinib + 80 mg PictilisibS1 C2: 20 mg Cobimetinib + 100 mg PictilisibS1 C3: 40 mg Cobimetinib + 80 mg PictilisibS1 C4: 40 mg Cobimetinib + 100 mg PictilisibS1 C5: 40 mg Cobimetinib + 130 mg PictilisibS1 C6: 60 mg Cobimetinib + 100 mg PictilisibS1 C6A: 80 mg Cobimetinib + 100 mg Pictilisib
t1/2 of Pictilisib on Cycle 1 Day 21 (Cycle 1 Day 28 for Cohorts 1-3) - Stage 1 All Cohorts25.8 (NA to NA)——NA (NA to NA)24.7 (22 to 30)27.7 (22 to 41)—
SecondaryCL/F of Pictilisib on Cycle 1 Day 21 (Cycle 1 Day 28 for Cohorts 1-3) - Stage 1 All Cohorts

Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.

Time frame:
Cohorts 1-3: Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 28, Cycle 1 Day 29, Cycle 2 Days 1, 15, 21; Cohorts 4-6A: Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 21, Cycle 1 Day 22, Cycle 2 Days 1, 15, 21
Reported as:
Geometric mean · L/hr
CL/F of Pictilisib on Cycle 1 Day 21 (Cycle 1 Day 28 for Cohorts 1-3) - Stage 1 All Cohorts
L/hrS1 C1: 20 mg Cobimetinib + 80 mg PictilisibS1 C2: 20 mg Cobimetinib + 100 mg PictilisibS1 C3: 40 mg Cobimetinib + 80 mg PictilisibS1 C4: 40 mg Cobimetinib + 100 mg PictilisibS1 C5: 40 mg Cobimetinib + 130 mg PictilisibS1 C6: 60 mg Cobimetinib + 100 mg PictilisibS1 C6A: 80 mg Cobimetinib + 100 mg Pictilisib
CL/F of Pictilisib on Cycle 1 Day 21 (Cycle 1 Day 28 for Cohorts 1-3) - Stage 1 All Cohorts32.0 ± 2134.1 ± 15014.5 ± 3425.7 ± 6330.1 ± 5822.2 ± 4024.6 ± NA
SecondaryAccumulation Ratio of Pictilisib on Cycle 1 Day 21 (Cycle 1 Day 28 for Cohorts 1-3) - Stage 1 All Cohorts

Accumulation ratio was calculated as: AUC0-24 at Cycle 1 Day 21 (Cycle 1 Day 28 for Cohorts 1-3) divided by AUC0-24 at Cycle 1 Day 1 (Cycle 1 Day 8 for Cohorts 1-3).

Time frame:
Cohorts 1-3: Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Days 8 and 28, Cycle 1 Days 9, 29; Cohorts 4-6A: Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Days 1 and 21, Cycle 1 Day 2, 22
Reported as:
Geometric mean · ratio
Accumulation Ratio of Pictilisib on Cycle 1 Day 21 (Cycle 1 Day 28 for Cohorts 1-3) - Stage 1 All Cohorts
ratioS1 C1: 20 mg Cobimetinib + 80 mg PictilisibS1 C2: 20 mg Cobimetinib + 100 mg PictilisibS1 C3: 40 mg Cobimetinib + 80 mg PictilisibS1 C4: 40 mg Cobimetinib + 100 mg PictilisibS1 C5: 40 mg Cobimetinib + 130 mg PictilisibS1 C6: 60 mg Cobimetinib + 100 mg PictilisibS1 C6A: 80 mg Cobimetinib + 100 mg Pictilisib
Accumulation Ratio of Pictilisib on Cycle 1 Day 21 (Cycle 1 Day 28 for Cohorts 1-3) - Stage 1 All Cohorts1.51 ± 471.36 ± 792.11 ± 6.01.16 ± 341.71 ± 291.70 ± 252.8 ± NA
SecondaryTmax of Cobimetinib on Cycle 1 Day 1 - Stage 1A All Cohorts
Time frame:
Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 1, Cycle 1 Days 2, 8, 15-17
Reported as:
Median · hours
Tmax of Cobimetinib on Cycle 1 Day 1 - Stage 1A All Cohorts
hoursS1A CA: 100 mg Cobimetinib + 130 mg PictilisibS1A CB: 100 mg Cobimetinib + 180 mg PictilisibS1A CC: 125 mg Cobimetinib + 130 mg PictilisibS1A CD: 125 mg Cobimetinib + 180 mg PictilisibS1A CE: 125 mg Cobimetinib + 245 mg PictilisibS1A CF: 150 mg Cobimetinib + 180 mg PictilisibS1A CG: 150 mg Cobimetinib + 245 mg Pictilisib
Tmax of Cobimetinib on Cycle 1 Day 1 - Stage 1A All Cohorts2.00 (2.0 to 4.0)4.00 (2.0 to 6.0)2.00 (1.0 to 2.0)4.00 (2.0 to 24)4.00 (2.0 to 6.0)5.00 (2.0 to 24)4.00 (2.0 to 6.0)
SecondaryCmax of Cobimetinib on Cycle 1 Day 1 - Stage 1A All Cohorts
Time frame:
Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 1, Cycle 1 Days 2, 8, 15-17
Reported as:
Geometric mean · ng/mL
Cmax of Cobimetinib on Cycle 1 Day 1 - Stage 1A All Cohorts
ng/mLS1A CA: 100 mg Cobimetinib + 130 mg PictilisibS1A CB: 100 mg Cobimetinib + 180 mg PictilisibS1A CC: 125 mg Cobimetinib + 130 mg PictilisibS1A CD: 125 mg Cobimetinib + 180 mg PictilisibS1A CE: 125 mg Cobimetinib + 245 mg PictilisibS1A CF: 150 mg Cobimetinib + 180 mg PictilisibS1A CG: 150 mg Cobimetinib + 245 mg Pictilisib
Cmax of Cobimetinib on Cycle 1 Day 1 - Stage 1A All Cohorts301 ± 87137 ± 66436 ± 67184 ± 47275 ± 72333 ± 45311 ± 48
SecondaryAUC0-24 of Cobimetinib on Cycle 1 Day 1 - Stage 1A All Cohorts
Time frame:
Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 1, Cycle 1 Days 2
Reported as:
Geometric mean · ng*h/mL
AUC0-24 of Cobimetinib on Cycle 1 Day 1 - Stage 1A All Cohorts
ng*h/mLS1A CA: 100 mg Cobimetinib + 130 mg PictilisibS1A CB: 100 mg Cobimetinib + 180 mg PictilisibS1A CC: 125 mg Cobimetinib + 130 mg PictilisibS1A CD: 125 mg Cobimetinib + 180 mg PictilisibS1A CE: 125 mg Cobimetinib + 245 mg PictilisibS1A CF: 150 mg Cobimetinib + 180 mg PictilisibS1A CG: 150 mg Cobimetinib + 245 mg Pictilisib
AUC0-24 of Cobimetinib on Cycle 1 Day 1 - Stage 1A All Cohorts4950 ± 802320 ± 615520 ± 592620 ± 504250 ± 755100 ± 475090 ± 45
SecondaryTmax of Cobimetinib on Cycle 1 Day 18 - Stage 1A All Cohorts
Time frame:
Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 18, Cycle 1 Day 19, Cycle 2 Days 1, 15, 21
Reported as:
Median · hours
Tmax of Cobimetinib on Cycle 1 Day 18 - Stage 1A All Cohorts
hoursS1A CA: 100 mg Cobimetinib + 130 mg PictilisibS1A CB: 100 mg Cobimetinib + 180 mg PictilisibS1A CC: 125 mg Cobimetinib + 130 mg PictilisibS1A CD: 125 mg Cobimetinib + 180 mg PictilisibS1A CE: 125 mg Cobimetinib + 245 mg PictilisibS1A CF: 150 mg Cobimetinib + 180 mg PictilisibS1A CG: 150 mg Cobimetinib + 245 mg Pictilisib
Tmax of Cobimetinib on Cycle 1 Day 18 - Stage 1A All Cohorts2.00 (2.0 to 4.0)2.00 (2.0 to 2.0)2.00 (2.0 to 6.0)4.00 (2.0 to 6.0)4.00 (2.0 to 6.0)5.00 (2.0 to 24)3.00 (2.0 to 4.0)
SecondaryCmax of Cobimetinib on Cycle 1 Day 18 - Stage 1A All Cohorts
Time frame:
Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 18, Cycle 1 Day 19, Cycle 2 Days 1, 15, 21
Reported as:
Geometric mean · ng/mL
Cmax of Cobimetinib on Cycle 1 Day 18 - Stage 1A All Cohorts
ng/mLS1A CA: 100 mg Cobimetinib + 130 mg PictilisibS1A CB: 100 mg Cobimetinib + 180 mg PictilisibS1A CC: 125 mg Cobimetinib + 130 mg PictilisibS1A CD: 125 mg Cobimetinib + 180 mg PictilisibS1A CE: 125 mg Cobimetinib + 245 mg PictilisibS1A CF: 150 mg Cobimetinib + 180 mg PictilisibS1A CG: 150 mg Cobimetinib + 245 mg Pictilisib
Cmax of Cobimetinib on Cycle 1 Day 18 - Stage 1A All Cohorts802 ± 24372 ± 45616 ± 39204 ± 57409 ± 43475 ± 86682 ± 23
SecondaryAUC0-24 of Cobimetinib on Cycle 1 Day 18 - Stage 1A All Cohorts
Time frame:
Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 18, Cycle 1 Day 19
Reported as:
Geometric mean · ng*h/mL
AUC0-24 of Cobimetinib on Cycle 1 Day 18 - Stage 1A All Cohorts
ng*h/mLS1A CA: 100 mg Cobimetinib + 130 mg PictilisibS1A CB: 100 mg Cobimetinib + 180 mg PictilisibS1A CC: 125 mg Cobimetinib + 130 mg PictilisibS1A CD: 125 mg Cobimetinib + 180 mg PictilisibS1A CE: 125 mg Cobimetinib + 245 mg PictilisibS1A CF: 150 mg Cobimetinib + 180 mg PictilisibS1A CG: 150 mg Cobimetinib + 245 mg Pictilisib
AUC0-24 of Cobimetinib on Cycle 1 Day 18 - Stage 1A All Cohorts13400 ± 185680 ± 559990 ± 283060 ± 506980 ± 557740 ± 6911100 ± 23
Secondaryt1/2 of Cobimetinib on Cycle 1 Day 18 - Stage 1A All Cohorts

Half-life is the time measured for the plasma concentration to decrease by one half.

Time frame:
Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 18, Cycle 1 Day 19, Cycle 2 Days 1, 15, 21
Reported as:
Geometric mean · hours
t1/2 of Cobimetinib on Cycle 1 Day 18 - Stage 1A All Cohorts
hoursS1A CA: 100 mg Cobimetinib + 130 mg PictilisibS1A CB: 100 mg Cobimetinib + 180 mg PictilisibS1A CC: 125 mg Cobimetinib + 130 mg PictilisibS1A CD: 125 mg Cobimetinib + 180 mg PictilisibS1A CE: 125 mg Cobimetinib + 245 mg PictilisibS1A CF: 150 mg Cobimetinib + 180 mg PictilisibS1A CG: 150 mg Cobimetinib + 245 mg Pictilisib
t1/2 of Cobimetinib on Cycle 1 Day 18 - Stage 1A All CohortsNA (NA to NA)46.1 (32 to 67)47.4 (34 to 63)48.8 (37 to 63)48 (36 to 72)NA (NA to NA)46.2 (33 to 55)
SecondaryCL/F of Cobimetinib on Cycle 1 Day 18 - Stage 1A All Cohorts

Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.

Time frame:
Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 18, Cycle 1 Day 19, Cycle 2 Days 1, 15, 21
Reported as:
Geometric mean · L/hr
CL/F of Cobimetinib on Cycle 1 Day 18 - Stage 1A All Cohorts
L/hrS1A CA: 100 mg Cobimetinib + 130 mg PictilisibS1A CB: 100 mg Cobimetinib + 180 mg PictilisibS1A CC: 125 mg Cobimetinib + 130 mg PictilisibS1A CD: 125 mg Cobimetinib + 180 mg PictilisibS1A CE: 125 mg Cobimetinib + 245 mg PictilisibS1A CF: 150 mg Cobimetinib + 180 mg PictilisibS1A CG: 150 mg Cobimetinib + 245 mg Pictilisib
CL/F of Cobimetinib on Cycle 1 Day 18 - Stage 1A All Cohorts7.49 ± 1817.6 ± 5512.5 ± 2840.9 ± 5017.9 ± 5519.4 ± 6913.6 ± 23
SecondaryAccumulation Ratio of Cobimetinib on Cycle 1 Day 18 - Stage 1A All Cohorts

Accumulation ratio was calculated as: AUC0-24 at Cycle 1 Day 18 divided by AUC0-24 at Cycle 1 Day 1.

Time frame:
Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Days 1 and 18, Cycle 1 Days 2, 19
Reported as:
Geometric mean · ratio
Accumulation Ratio of Cobimetinib on Cycle 1 Day 18 - Stage 1A All Cohorts
ratioS1A CA: 100 mg Cobimetinib + 130 mg PictilisibS1A CB: 100 mg Cobimetinib + 180 mg PictilisibS1A CC: 125 mg Cobimetinib + 130 mg PictilisibS1A CD: 125 mg Cobimetinib + 180 mg PictilisibS1A CE: 125 mg Cobimetinib + 245 mg PictilisibS1A CF: 150 mg Cobimetinib + 180 mg PictilisibS1A CG: 150 mg Cobimetinib + 245 mg Pictilisib
Accumulation Ratio of Cobimetinib on Cycle 1 Day 18 - Stage 1A All Cohorts2.70 ± 572.44 ± 601.46 ± 301.11 ± 671.52 ± 1201.75 ± 401.84 ± 8.1
SecondaryTmax of Pictilisib on Cycle 1 Day 1 - Stage 1A All Cohorts
Time frame:
Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 1, Cycle 1 Days 2, 8, 15-17
Reported as:
Median · hours
Tmax of Pictilisib on Cycle 1 Day 1 - Stage 1A All Cohorts
hoursS1A CA: 100 mg Cobimetinib + 130 mg PictilisibS1A CB: 100 mg Cobimetinib + 180 mg PictilisibS1A CC: 125 mg Cobimetinib + 130 mg PictilisibS1A CD: 125 mg Cobimetinib + 180 mg PictilisibS1A CE: 125 mg Cobimetinib + 245 mg PictilisibS1A CF: 150 mg Cobimetinib + 180 mg PictilisibS1A CG: 150 mg Cobimetinib + 245 mg Pictilisib
Tmax of Pictilisib on Cycle 1 Day 1 - Stage 1A All Cohorts2.00 (2.0 to 4.0)2.00 (2.0 to 2.0)2.00 (2.0 to 2.0)2.00 (2.0 to 24)2.00 (2.0 to 4.0)2.00 (0.5 to 6.0)4.00 (0.5 to 6.0)
SecondaryCmax of Pictilisib on Cycle 1 Day 1 - Stage 1A All Cohorts
Time frame:
Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 1, Cycle 1 Days 2, 8, 15-17
Reported as:
Geometric mean · ng/mL
Cmax of Pictilisib on Cycle 1 Day 1 - Stage 1A All Cohorts
ng/mLS1A CA: 100 mg Cobimetinib + 130 mg PictilisibS1A CB: 100 mg Cobimetinib + 180 mg PictilisibS1A CC: 125 mg Cobimetinib + 130 mg PictilisibS1A CD: 125 mg Cobimetinib + 180 mg PictilisibS1A CE: 125 mg Cobimetinib + 245 mg PictilisibS1A CF: 150 mg Cobimetinib + 180 mg PictilisibS1A CG: 150 mg Cobimetinib + 245 mg Pictilisib
Cmax of Pictilisib on Cycle 1 Day 1 - Stage 1A All Cohorts547 ± 80408 ± 190390 ± 76367 ± 61832 ± 35619 ± 110514 ± 81
SecondaryAUC0-24 of Pictilisib on Cycle 1 Day 1 - Stage 1A All Cohorts
Time frame:
Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 1, Cycle 1 Days 2
Reported as:
Geometric mean · ng*h/mL
AUC0-24 of Pictilisib on Cycle 1 Day 1 - Stage 1A All Cohorts
ng*h/mLS1A CA: 100 mg Cobimetinib + 130 mg PictilisibS1A CB: 100 mg Cobimetinib + 180 mg PictilisibS1A CC: 125 mg Cobimetinib + 130 mg PictilisibS1A CD: 125 mg Cobimetinib + 180 mg PictilisibS1A CE: 125 mg Cobimetinib + 245 mg PictilisibS1A CF: 150 mg Cobimetinib + 180 mg PictilisibS1A CG: 150 mg Cobimetinib + 245 mg Pictilisib
AUC0-24 of Pictilisib on Cycle 1 Day 1 - Stage 1A All Cohorts6900 ± 624900 ± 1703670 ± 724280 ± 488440 ± 325650 ± 886680 ± 53
SecondaryTmax of Pictilisib on Cycle 1 Day 18 - Stage 1A All Cohorts
Time frame:
Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 18, Cycle 1 Day 19, Cycle 2 Days 1, 15, 21
Reported as:
Median · hours
Tmax of Pictilisib on Cycle 1 Day 18 - Stage 1A All Cohorts
hoursS1A CA: 100 mg Cobimetinib + 130 mg PictilisibS1A CB: 100 mg Cobimetinib + 180 mg PictilisibS1A CC: 125 mg Cobimetinib + 130 mg PictilisibS1A CD: 125 mg Cobimetinib + 180 mg PictilisibS1A CE: 125 mg Cobimetinib + 245 mg PictilisibS1A CF: 150 mg Cobimetinib + 180 mg PictilisibS1A CG: 150 mg Cobimetinib + 245 mg Pictilisib
Tmax of Pictilisib on Cycle 1 Day 18 - Stage 1A All Cohorts2.00 (2.0 to 4.0)2.00 (2.0 to 2.0)2.00 (0.5 to 2.0)2.00 (2.0 to 2.0)3.00 (2.0 to 6.0)2.00 (0.5 to 6.0)3.00 (2.0 to 24)
SecondaryCmax of Pictilisib on Cycle 1 Day 18 - Stage 1A All Cohorts
Time frame:
Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 18, Cycle 1 Day 19, Cycle 2 Days 1, 15, 21
Reported as:
Geometric mean · ng/mL
Cmax of Pictilisib on Cycle 1 Day 18 - Stage 1A All Cohorts
ng/mLS1A CA: 100 mg Cobimetinib + 130 mg PictilisibS1A CB: 100 mg Cobimetinib + 180 mg PictilisibS1A CC: 125 mg Cobimetinib + 130 mg PictilisibS1A CD: 125 mg Cobimetinib + 180 mg PictilisibS1A CE: 125 mg Cobimetinib + 245 mg PictilisibS1A CF: 150 mg Cobimetinib + 180 mg PictilisibS1A CG: 150 mg Cobimetinib + 245 mg Pictilisib
Cmax of Pictilisib on Cycle 1 Day 18 - Stage 1A All Cohorts809 ± 41709 ± 71597 ± 38579 ± 100833 ± 49743 ± 53646 ± 24
SecondaryAUC0-24 of Pictilisib on Cycle 1 Day 18 - Stage 1A All Cohorts
Time frame:
Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 18, Cycle 1 Day 19
Reported as:
Geometric mean · ng*h/mL
AUC0-24 of Pictilisib on Cycle 1 Day 18 - Stage 1A All Cohorts
ng*h/mLS1A CA: 100 mg Cobimetinib + 130 mg PictilisibS1A CB: 100 mg Cobimetinib + 180 mg PictilisibS1A CC: 125 mg Cobimetinib + 130 mg PictilisibS1A CD: 125 mg Cobimetinib + 180 mg PictilisibS1A CE: 125 mg Cobimetinib + 245 mg PictilisibS1A CF: 150 mg Cobimetinib + 180 mg PictilisibS1A CG: 150 mg Cobimetinib + 245 mg Pictilisib
AUC0-24 of Pictilisib on Cycle 1 Day 18 - Stage 1A All Cohorts11300 ± 217680 ± 886990 ± 386120 ± 11012100 ± 588140 ± 5810100 ± 44
Secondaryt1/2 of Pictilisib on Cycle 1 Day 18 - Stage 1A All Cohorts

Half-life is the time measured for the plasma concentration to decrease by one half. As planned, summary statistics were not derived if fewer than 3 participants had available data; however, if the number of participants analyzed = 1, then the observed data of the single participant was reported as geometric mean.

Time frame:
Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 18, Cycle 1 Day 19, Cycle 2 Days 1, 15, 21
Reported as:
Geometric mean · hours
t1/2 of Pictilisib on Cycle 1 Day 18 - Stage 1A All Cohorts
hoursS1A CA: 100 mg Cobimetinib + 130 mg PictilisibS1A CB: 100 mg Cobimetinib + 180 mg PictilisibS1A CC: 125 mg Cobimetinib + 130 mg PictilisibS1A CD: 125 mg Cobimetinib + 180 mg PictilisibS1A CE: 125 mg Cobimetinib + 245 mg PictilisibS1A CF: 150 mg Cobimetinib + 180 mg PictilisibS1A CG: 150 mg Cobimetinib + 245 mg Pictilisib
t1/2 of Pictilisib on Cycle 1 Day 18 - Stage 1A All CohortsNA (NA to NA)NA (NA to NA)34.9 (29 to 44)36.5 (NA to NA)38.4 (27 to 52)NA (NA to NA)NA (NA to NA)
SecondaryCL/F of Pictilisib on Cycle 1 Day 18 - Stage 1A All Cohorts

Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.

Time frame:
Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 18, Cycle 1 Day 19, Cycle 2 Days 1, 15, 21
Reported as:
Geometric mean · L/hr
CL/F of Pictilisib on Cycle 1 Day 18 - Stage 1A All Cohorts
L/hrS1A CA: 100 mg Cobimetinib + 130 mg PictilisibS1A CB: 100 mg Cobimetinib + 180 mg PictilisibS1A CC: 125 mg Cobimetinib + 130 mg PictilisibS1A CD: 125 mg Cobimetinib + 180 mg PictilisibS1A CE: 125 mg Cobimetinib + 245 mg PictilisibS1A CF: 150 mg Cobimetinib + 180 mg PictilisibS1A CG: 150 mg Cobimetinib + 245 mg Pictilisib
CL/F of Pictilisib on Cycle 1 Day 18 - Stage 1A All Cohorts11.5 ± 2123.5 ± 8818.6 ± 3829.4 ± 11020.3 ± 5822.1 ± 5824.2 ± 44
SecondaryAccumulation Ratio of Pictilisib on Cycle 1 Day 18 - Stage 1A All Cohorts

Accumulation ratio was calculated as: AUC0-24 at Cycle 1 Day 18 divided by AUC0-24 at Cycle 1 Day 1.

Time frame:
Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Days 1 and 18, Cycle 1 Days 2, 19
Reported as:
Geometric mean · ratio
Accumulation Ratio of Pictilisib on Cycle 1 Day 18 - Stage 1A All Cohorts
ratioS1A CA: 100 mg Cobimetinib + 130 mg PictilisibS1A CB: 100 mg Cobimetinib + 180 mg PictilisibS1A CC: 125 mg Cobimetinib + 130 mg PictilisibS1A CD: 125 mg Cobimetinib + 180 mg PictilisibS1A CE: 125 mg Cobimetinib + 245 mg PictilisibS1A CF: 150 mg Cobimetinib + 180 mg PictilisibS1A CG: 150 mg Cobimetinib + 245 mg Pictilisib
Accumulation Ratio of Pictilisib on Cycle 1 Day 18 - Stage 1A All Cohorts1.64 ± 401.57 ± 451.89 ± 1101.15 ± 551.56 ± 421.60 ± 1001.46 ± 100
SecondaryTmax of Cobimetinib on Cycle 1 Day 1 - Stage 1B All Cohorts
Time frame:
Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 1, Cycle 1 Day 2
Reported as:
Median · hours
Tmax of Cobimetinib on Cycle 1 Day 1 - Stage 1B All Cohorts
hoursS1B CAX: 40 mg Cobimetinib + 130 mg PictilisibS1B CBX: 40 mg Cobimetinib + 180 mg PictilisibS1B CCX: 60 mg Cobimetinib + 130 mg PictilisibS1B CDX: 60 mg Cobimetinib + 180 mg Pictilisib
Tmax of Cobimetinib on Cycle 1 Day 1 - Stage 1B All Cohorts3.00 (2.0 to 6.0)2.00 (2.0 to 4.0)4.00 (2.0 to 24)4.00 (0 to 6.0)
SecondaryCmax of Cobimetinib on Cycle 1 Day 1 - Stage 1B All Cohorts
Time frame:
Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 1, Cycle 1 Day 2
Reported as:
Geometric mean · ng/mL
Cmax of Cobimetinib on Cycle 1 Day 1 - Stage 1B All Cohorts
ng/mLS1B CAX: 40 mg Cobimetinib + 130 mg PictilisibS1B CBX: 40 mg Cobimetinib + 180 mg PictilisibS1B CCX: 60 mg Cobimetinib + 130 mg PictilisibS1B CDX: 60 mg Cobimetinib + 180 mg Pictilisib
Cmax of Cobimetinib on Cycle 1 Day 1 - Stage 1B All Cohorts55 ± 160123 ± 5645.6 ± 11077.8 ± 110
SecondaryAUC0-24 of Cobimetinib on Cycle 1 Day 1 - Stage 1B All Cohorts
Time frame:
Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 1, Cycle 1 Day 2
Reported as:
Geometric mean · ng*h/mL
AUC0-24 of Cobimetinib on Cycle 1 Day 1 - Stage 1B All Cohorts
ng*h/mLS1B CAX: 40 mg Cobimetinib + 130 mg PictilisibS1B CBX: 40 mg Cobimetinib + 180 mg PictilisibS1B CCX: 60 mg Cobimetinib + 130 mg PictilisibS1B CDX: 60 mg Cobimetinib + 180 mg Pictilisib
AUC0-24 of Cobimetinib on Cycle 1 Day 1 - Stage 1B All Cohorts855 ± 1501750 ± 77699 ± 722460 ± NA
SecondaryTmax of Cobimetinib on Cycle 1 Day 21 - Stage 1B All Cohorts
Time frame:
Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 21, Cycle 1 Day 22
Reported as:
Median · hours
Tmax of Cobimetinib on Cycle 1 Day 21 - Stage 1B All Cohorts
hoursS1B CAX: 40 mg Cobimetinib + 130 mg PictilisibS1B CBX: 40 mg Cobimetinib + 180 mg PictilisibS1B CCX: 60 mg Cobimetinib + 130 mg PictilisibS1B CDX: 60 mg Cobimetinib + 180 mg Pictilisib
Tmax of Cobimetinib on Cycle 1 Day 21 - Stage 1B All Cohorts5.00 (2.0 to 6.0)4.00 (2.0 to 6.0)2.00 (0 to 6.0)6.00 (2.0 to 6.0)
SecondaryCmax of Cobimetinib on Cycle 1 Day 21 - Stage 1B All Cohorts
Time frame:
Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 21, Cycle 1 Day 22
Reported as:
Geometric mean · ng/mL
Cmax of Cobimetinib on Cycle 1 Day 21 - Stage 1B All Cohorts
ng/mLS1B CAX: 40 mg Cobimetinib + 130 mg PictilisibS1B CBX: 40 mg Cobimetinib + 180 mg PictilisibS1B CCX: 60 mg Cobimetinib + 130 mg PictilisibS1B CDX: 60 mg Cobimetinib + 180 mg Pictilisib
Cmax of Cobimetinib on Cycle 1 Day 21 - Stage 1B All Cohorts174 ± 50232 ± 120158 ± 73245 ± 45
SecondaryAUC0-24 of Cobimetinib on Cycle 1 Day 21 - Stage 1B All Cohorts
Time frame:
Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 21, Cycle 1 Day 22
Reported as:
Geometric mean · ng*h/mL
AUC0-24 of Cobimetinib on Cycle 1 Day 21 - Stage 1B All Cohorts
ng*h/mLS1B CAX: 40 mg Cobimetinib + 130 mg PictilisibS1B CBX: 40 mg Cobimetinib + 180 mg PictilisibS1B CCX: 60 mg Cobimetinib + 130 mg PictilisibS1B CDX: 60 mg Cobimetinib + 180 mg Pictilisib
AUC0-24 of Cobimetinib on Cycle 1 Day 21 - Stage 1B All Cohorts3270 ± 644320 ± 150NA ± NA4190 ± 52
SecondaryCL/F of Cobimetinib on Cycle 1 Day 21 - Stage 1B All Cohorts

Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.

Time frame:
Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 21, Cycle 1 Day 22
Reported as:
Geometric mean · L/hr
CL/F of Cobimetinib on Cycle 1 Day 21 - Stage 1B All Cohorts
L/hrS1B CAX: 40 mg Cobimetinib + 130 mg PictilisibS1B CBX: 40 mg Cobimetinib + 180 mg PictilisibS1B CCX: 60 mg Cobimetinib + 130 mg PictilisibS1B CDX: 60 mg Cobimetinib + 180 mg Pictilisib
CL/F of Cobimetinib on Cycle 1 Day 21 - Stage 1B All Cohorts12.2 ± 649.26 ± 150NA ± NA14.3 ± 52
SecondaryAccumulation Ratio of Cobimetinib on Cycle 1 Day 21 - Stage 1B All Cohorts

Accumulation ratio was calculated as: AUC0-24 at Cycle 1 Day 21 divided by AUC0-24 at Cycle 1 Day 1.

Time frame:
Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Days 1 and 21, Cycle 1 Days 2 and 22
Reported as:
Geometric mean · ratio
Accumulation Ratio of Cobimetinib on Cycle 1 Day 21 - Stage 1B All Cohorts
ratioS1B CAX: 40 mg Cobimetinib + 130 mg PictilisibS1B CBX: 40 mg Cobimetinib + 180 mg PictilisibS1B CCX: 60 mg Cobimetinib + 130 mg PictilisibS1B CDX: 60 mg Cobimetinib + 180 mg Pictilisib
Accumulation Ratio of Cobimetinib on Cycle 1 Day 21 - Stage 1B All Cohorts3.82 ± 602.46 ± 46NA ± NA1.15 ± 57
SecondaryTmax of Pictilisib on Cycle 1 Day 1 - Stage 1B All Cohorts
Time frame:
Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 1, Cycle 1 Day 2
Reported as:
Median · hours
Tmax of Pictilisib on Cycle 1 Day 1 - Stage 1B All Cohorts
hoursS1B CAX: 40 mg Cobimetinib + 130 mg PictilisibS1B CBX: 40 mg Cobimetinib + 180 mg PictilisibS1B CCX: 60 mg Cobimetinib + 130 mg PictilisibS1B CDX: 60 mg Cobimetinib + 180 mg Pictilisib
Tmax of Pictilisib on Cycle 1 Day 1 - Stage 1B All Cohorts2.00 (2.0 to 2.0)2.00 (2.0 to 6.0)2.00 (2.0 to 24)4.00 (2.0 to 6.0)
SecondaryCmax of Pictilisib on Cycle 1 Day 1 - Stage 1B All Cohorts
Time frame:
Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 1, Cycle 1 Day 2
Reported as:
Geometric mean · ng/mL
Cmax of Pictilisib on Cycle 1 Day 1 - Stage 1B All Cohorts
ng/mLS1B CAX: 40 mg Cobimetinib + 130 mg PictilisibS1B CBX: 40 mg Cobimetinib + 180 mg PictilisibS1B CCX: 60 mg Cobimetinib + 130 mg PictilisibS1B CDX: 60 mg Cobimetinib + 180 mg Pictilisib
Cmax of Pictilisib on Cycle 1 Day 1 - Stage 1B All Cohorts527 ± 67609 ± 27168 ± 130363 ± 64
SecondaryAUC0-24 of Pictilisib on Cycle 1 Day 1 - Stage 1B All Cohorts
Time frame:
Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 1, Cycle 1 Day 2
Reported as:
Geometric mean · ng*h/mL
AUC0-24 of Pictilisib on Cycle 1 Day 1 - Stage 1B All Cohorts
ng*h/mLS1B CAX: 40 mg Cobimetinib + 130 mg PictilisibS1B CBX: 40 mg Cobimetinib + 180 mg PictilisibS1B CCX: 60 mg Cobimetinib + 130 mg PictilisibS1B CDX: 60 mg Cobimetinib + 180 mg Pictilisib
AUC0-24 of Pictilisib on Cycle 1 Day 1 - Stage 1B All Cohorts5380 ± 506540 ± 202260 ± 704160 ± 77
SecondaryTmax of Pictilisib on Cycle 1 Day 21 - Stage 1B All Cohorts
Time frame:
Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 21, Cycle 1 Day 22
Reported as:
Median · hours
Tmax of Pictilisib on Cycle 1 Day 21 - Stage 1B All Cohorts
hoursS1B CAX: 40 mg Cobimetinib + 130 mg PictilisibS1B CBX: 40 mg Cobimetinib + 180 mg PictilisibS1B CCX: 60 mg Cobimetinib + 130 mg PictilisibS1B CDX: 60 mg Cobimetinib + 180 mg Pictilisib
Tmax of Pictilisib on Cycle 1 Day 21 - Stage 1B All Cohorts4.00 (0.5 to 6.0)2.00 (2.0 to 4.0)4.00 (2.0 to 6.0)5.00 (0 to 6.0)
SecondaryCmax of Pictilisib on Cycle 1 Day 21 - Stage 1B All Cohorts
Time frame:
Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 21, Cycle 1 Day 22
Reported as:
Geometric mean · ng/mL
Cmax of Pictilisib on Cycle 1 Day 21 - Stage 1B All Cohorts
ng/mLS1B CAX: 40 mg Cobimetinib + 130 mg PictilisibS1B CBX: 40 mg Cobimetinib + 180 mg PictilisibS1B CCX: 60 mg Cobimetinib + 130 mg PictilisibS1B CDX: 60 mg Cobimetinib + 180 mg Pictilisib
Cmax of Pictilisib on Cycle 1 Day 21 - Stage 1B All Cohorts508 ± 101010 ± 27227 ± 19408 ± 62
SecondaryAUC0-24 of Pictilisib on Cycle 1 Day 21 - Stage 1B All Cohorts
Time frame:
Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 21, Cycle 1 Day 22
Reported as:
Geometric mean · ng*h/mL
AUC0-24 of Pictilisib on Cycle 1 Day 21 - Stage 1B All Cohorts
ng*h/mLS1B CAX: 40 mg Cobimetinib + 130 mg PictilisibS1B CBX: 40 mg Cobimetinib + 180 mg PictilisibS1B CCX: 60 mg Cobimetinib + 130 mg PictilisibS1B CDX: 60 mg Cobimetinib + 180 mg Pictilisib
AUC0-24 of Pictilisib on Cycle 1 Day 21 - Stage 1B All Cohorts7000 ± 1213500 ± 39NA ± NA5410 ± 57
SecondaryCL/F of Pictilisib on Cycle 1 Day 21 - Stage 1B All Cohorts

Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.

Time frame:
Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 21, Cycle 1 Day 22
Reported as:
Geometric mean · L/hr
CL/F of Pictilisib on Cycle 1 Day 21 - Stage 1B All Cohorts
L/hrS1B CAX: 40 mg Cobimetinib + 130 mg PictilisibS1B CBX: 40 mg Cobimetinib + 180 mg PictilisibS1B CCX: 60 mg Cobimetinib + 130 mg PictilisibS1B CDX: 60 mg Cobimetinib + 180 mg Pictilisib
CL/F of Pictilisib on Cycle 1 Day 21 - Stage 1B All Cohorts18.6 ± 1213.3 ± 39NA ± NA33.3 ± 57
SecondaryAccumulation Ratio of Pictilisib on Cycle 1 Day 21 - Stage 1B All Cohorts

Accumulation ratio was calculated as: AUC0-24 at Cycle 1 Day 21 divided by AUC0-24 at Cycle 1 Day 1.

Time frame:
Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Days 1 and 21, Cycle 1 Days 2 and 22
Reported as:
Geometric mean · ratio
Accumulation Ratio of Pictilisib on Cycle 1 Day 21 - Stage 1B All Cohorts
ratioS1B CAX: 40 mg Cobimetinib + 130 mg PictilisibS1B CBX: 40 mg Cobimetinib + 180 mg PictilisibS1B CCX: 60 mg Cobimetinib + 130 mg PictilisibS1B CDX: 60 mg Cobimetinib + 180 mg Pictilisib
Accumulation Ratio of Pictilisib on Cycle 1 Day 21 - Stage 1B All Cohorts1.30 ± 402.06 ± 19NA ± NA1.36 ± 57
SecondaryTmax of Cobimetinib on Cycle 1 Day 1 - Stage 2 Individual Indication Specific Cohorts

Stage 2 PK data were reported for each indication specific cohort separately.

Time frame:
Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 1, Cycle 1 Days 2, 8, 14
Reported as:
Median · hours
Tmax of Cobimetinib on Cycle 1 Day 1 - Stage 2 Individual Indication Specific Cohorts
hoursS2 EGFR T790M NSCLC: 40 mg Cobimetinib + 100 mg PictilisibS2 KRAS NSCLC: 40 mg Cobimetinib + 100 mg PictilisibS2 KRAS CRC: 40 mg Cobimetinib + 100 mg PictilisibS2 Pancreatic: 40 mg Cobimetinib + 100 mg Pictilisib
Tmax of Cobimetinib on Cycle 1 Day 1 - Stage 2 Individual Indication Specific Cohorts2.00 (2.0 to 6.0)4.00 (2.0 to 24)3.00 (2.0 to 6.0)4.00 (2.0 to 24)
SecondaryCmax of Cobimetinib on Cycle 1 Day 1 - Stage 2 Individual Indication Specific Cohorts

Stage 2 PK data were reported for each indication specific cohort separately.

Time frame:
Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 1, Cycle 1 Days 2, 8, 14
Reported as:
Geometric mean · ng/mL
Cmax of Cobimetinib on Cycle 1 Day 1 - Stage 2 Individual Indication Specific Cohorts
ng/mLS2 EGFR T790M NSCLC: 40 mg Cobimetinib + 100 mg PictilisibS2 KRAS NSCLC: 40 mg Cobimetinib + 100 mg PictilisibS2 KRAS CRC: 40 mg Cobimetinib + 100 mg PictilisibS2 Pancreatic: 40 mg Cobimetinib + 100 mg Pictilisib
Cmax of Cobimetinib on Cycle 1 Day 1 - Stage 2 Individual Indication Specific Cohorts73.8 ± 3890.7 ± 87116 ± 6348.2 ± 97
SecondaryAUC0-24 of Cobimetinib on Cycle 1 Day 1 - Stage 2 All Cohorts

Stage 2 PK data were reported for each indication specific cohort separately.

Time frame:
Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 1, Cycle 1 Days 2
Reported as:
Geometric mean · ng*h/mL
AUC0-24 of Cobimetinib on Cycle 1 Day 1 - Stage 2 All Cohorts
ng*h/mLS2 EGFR T790M NSCLC: 40 mg Cobimetinib + 100 mg PictilisibS2 KRAS NSCLC: 40 mg Cobimetinib + 100 mg PictilisibS2 KRAS CRC: 40 mg Cobimetinib + 100 mg PictilisibS2 Pancreatic: 40 mg Cobimetinib + 100 mg Pictilisib
AUC0-24 of Cobimetinib on Cycle 1 Day 1 - Stage 2 All Cohorts1080 ± 261330 ± 1001790 ± 73700 ± 84
SecondaryTmax of Cobimetinib on Cycle 1 Day 21 - Stage 2 Individual Indication Specific Cohorts

Stage 2 PK data were reported for each indication specific cohort separately.

Time frame:
Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 21, Cycle 1 Day 22, Cycle 2 Days 1, 15, 21
Reported as:
Median · hours
Tmax of Cobimetinib on Cycle 1 Day 21 - Stage 2 Individual Indication Specific Cohorts
hoursS2 EGFR T790M NSCLC: 40 mg Cobimetinib + 100 mg PictilisibS2 KRAS NSCLC: 40 mg Cobimetinib + 100 mg PictilisibS2 KRAS CRC: 40 mg Cobimetinib + 100 mg PictilisibS2 Pancreatic: 40 mg Cobimetinib + 100 mg Pictilisib
Tmax of Cobimetinib on Cycle 1 Day 21 - Stage 2 Individual Indication Specific Cohorts4.00 (2.0 to 6.0)4.00 (2.0 to 6.0)2.00 (2.0 to 6.0)NA (NA to NA)
SecondaryCmax of Cobimetinib on Cycle 1 Day 21 - Stage 2 Individual Indication Specific Cohorts

Stage 2 PK data were reported for each indication specific cohort separately.

Time frame:
Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 21, Cycle 1 Day 22, Cycle 2 Days 1, 15, 21
Reported as:
Geometric mean · ng/mL
Cmax of Cobimetinib on Cycle 1 Day 21 - Stage 2 Individual Indication Specific Cohorts
ng/mLS2 EGFR T790M NSCLC: 40 mg Cobimetinib + 100 mg PictilisibS2 KRAS NSCLC: 40 mg Cobimetinib + 100 mg PictilisibS2 KRAS CRC: 40 mg Cobimetinib + 100 mg PictilisibS2 Pancreatic: 40 mg Cobimetinib + 100 mg Pictilisib
Cmax of Cobimetinib on Cycle 1 Day 21 - Stage 2 Individual Indication Specific Cohorts119 ± 62237 ± 63254 ± 120NA ± NA
SecondaryAUC0-24 of Cobimetinib on Cycle 1 Day 21 - Stage 2 Individual Indication Specific Cohorts

Stage 2 PK data were reported for each indication specific cohort separately.

Time frame:
Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 21, Cycle 1 Day 22
Reported as:
Geometric mean · ng*h/mL
AUC0-24 of Cobimetinib on Cycle 1 Day 21 - Stage 2 Individual Indication Specific Cohorts
ng*h/mLS2 EGFR T790M NSCLC: 40 mg Cobimetinib + 100 mg PictilisibS2 KRAS NSCLC: 40 mg Cobimetinib + 100 mg PictilisibS2 KRAS CRC: 40 mg Cobimetinib + 100 mg PictilisibS2 Pancreatic: 40 mg Cobimetinib + 100 mg Pictilisib
AUC0-24 of Cobimetinib on Cycle 1 Day 21 - Stage 2 Individual Indication Specific Cohorts2200 ± 574570 ± 684700 ± 120NA ± NA
Secondaryt1/2 of Cobimetinib on Cycle 1 Day 21 - Stage 2 Individual Indication Specific Cohorts

Stage 2 PK data were reported for each indication specific cohort separately. Half-life is the time measured for the plasma concentration to decrease by one half.

Time frame:
Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 21, Cycle 1 Day 22
Reported as:
Geometric mean · hours
t1/2 of Cobimetinib on Cycle 1 Day 21 - Stage 2 Individual Indication Specific Cohorts
hoursS2 EGFR T790M NSCLC: 40 mg Cobimetinib + 100 mg PictilisibS2 KRAS NSCLC: 40 mg Cobimetinib + 100 mg PictilisibS2 KRAS CRC: 40 mg Cobimetinib + 100 mg PictilisibS2 Pancreatic: 40 mg Cobimetinib + 100 mg Pictilisib
t1/2 of Cobimetinib on Cycle 1 Day 21 - Stage 2 Individual Indication Specific Cohorts42.5 (40 to 45)51.5 (42 to 83)36.0 (28 to 44)NA (NA to NA)
SecondaryCL/F of Cobimetinib on Cycle 1 Day 21 - Stage 2 Individual Indication Specific Cohorts

Stage 2 PK data were reported for each indication specific cohort separately. Half-life is the time measured for the plasma concentration to decrease by one half. Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.

Time frame:
Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 21, Cycle 1 Day 22, Cycle 2 Days 1, 15, 21
Reported as:
Geometric mean · L/hr
CL/F of Cobimetinib on Cycle 1 Day 21 - Stage 2 Individual Indication Specific Cohorts
L/hrS2 EGFR T790M NSCLC: 40 mg Cobimetinib + 100 mg PictilisibS2 KRAS NSCLC: 40 mg Cobimetinib + 100 mg PictilisibS2 KRAS CRC: 40 mg Cobimetinib + 100 mg PictilisibS2 Pancreatic: 40 mg Cobimetinib + 100 mg Pictilisib
CL/F of Cobimetinib on Cycle 1 Day 21 - Stage 2 Individual Indication Specific Cohorts18.2 ± 578.76 ± 688.52 ± 120NA ± NA
SecondaryAccumulation Ratio of Cobimetinib on Cycle 1 Day 21 - Stage 2 Individual Indication Specific Cohorts

Stage 2 PK data were reported for each indication specific cohort separately. Accumulation ratio was calculated as: AUC0-24 at Cycle 1 Day 21 divided by AUC0-24 at Cycle 1 Day 1.

Time frame:
Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Days 1 and 21, Cycle 1 Days 2 and 22
Reported as:
Geometric mean · ratio
Accumulation Ratio of Cobimetinib on Cycle 1 Day 21 - Stage 2 Individual Indication Specific Cohorts
ratioS2 EGFR T790M NSCLC: 40 mg Cobimetinib + 100 mg PictilisibS2 KRAS NSCLC: 40 mg Cobimetinib + 100 mg PictilisibS2 KRAS CRC: 40 mg Cobimetinib + 100 mg PictilisibS2 Pancreatic: 40 mg Cobimetinib + 100 mg Pictilisib
Accumulation Ratio of Cobimetinib on Cycle 1 Day 21 - Stage 2 Individual Indication Specific Cohorts1.92 ± 513.28 ± 522.60 ± 63NA ± NA
SecondaryTmax of Pictilisib on Cycle 1 Day 1 - Stage 2 Individual Indication Specific Cohorts

Stage 2 PK data were reported for each indication specific cohort separately.

Time frame:
Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 1, Cycle 1 Days 2, 8, 14
Reported as:
Median · hours
Tmax of Pictilisib on Cycle 1 Day 1 - Stage 2 Individual Indication Specific Cohorts
hoursS2 EGFR T790M NSCLC: 40 mg Cobimetinib + 100 mg PictilisibS2 KRAS NSCLC: 40 mg Cobimetinib + 100 mg PictilisibS2 KRAS CRC: 40 mg Cobimetinib + 100 mg PictilisibS2 Pancreatic: 40 mg Cobimetinib + 100 mg Pictilisib
Tmax of Pictilisib on Cycle 1 Day 1 - Stage 2 Individual Indication Specific Cohorts2.00 (2.0 to 6.0)2.00 (0.5 to 6.0)2.00 (0.5 to 4.0)4.00 (2.0 to 24)
SecondaryCmax of Pictilisib on Cycle 1 Day 1 - Stage 2 Individual Indication Specific Cohorts

Stage 2 PK data were reported for each indication specific cohort separately.

Time frame:
Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 1, Cycle 1 Days 2, 8, 14
Reported as:
Geometric mean · ng/mL
Cmax of Pictilisib on Cycle 1 Day 1 - Stage 2 Individual Indication Specific Cohorts
ng/mLS2 EGFR T790M NSCLC: 40 mg Cobimetinib + 100 mg PictilisibS2 KRAS NSCLC: 40 mg Cobimetinib + 100 mg PictilisibS2 KRAS CRC: 40 mg Cobimetinib + 100 mg PictilisibS2 Pancreatic: 40 mg Cobimetinib + 100 mg Pictilisib
Cmax of Pictilisib on Cycle 1 Day 1 - Stage 2 Individual Indication Specific Cohorts298 ± 52355 ± 55315 ± 58253 ± 90
SecondaryAUC0-24 of Pictilisib on Cycle 1 Day 1 - Stage 2 Individual Indication Specific Cohorts

Stage 2 PK data were reported for each indication specific cohort separately.

Time frame:
Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 1, Cycle 1 Days 2
Reported as:
Geometric mean · ng*h/mL
AUC0-24 of Pictilisib on Cycle 1 Day 1 - Stage 2 Individual Indication Specific Cohorts
ng*h/mLS2 EGFR T790M NSCLC: 40 mg Cobimetinib + 100 mg PictilisibS2 KRAS NSCLC: 40 mg Cobimetinib + 100 mg PictilisibS2 KRAS CRC: 40 mg Cobimetinib + 100 mg PictilisibS2 Pancreatic: 40 mg Cobimetinib + 100 mg Pictilisib
AUC0-24 of Pictilisib on Cycle 1 Day 1 - Stage 2 Individual Indication Specific Cohorts3010 ± 373800 ± 633210 ± 593340 ± 78
SecondaryTmax of Pictilisib on Cycle 1 Day 21 - Stage 2 Individual Indication Specific Cohorts

Stage 2 PK data were reported for each indication specific cohort separately.

Time frame:
Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 21, Cycle 1 Day 22, Cycle 2 Days 1, 15, 21
Reported as:
Median · hours
Tmax of Pictilisib on Cycle 1 Day 21 - Stage 2 Individual Indication Specific Cohorts
hoursS2 EGFR T790M NSCLC: 40 mg Cobimetinib + 100 mg PictilisibS2 KRAS NSCLC: 40 mg Cobimetinib + 100 mg PictilisibS2 KRAS CRC: 40 mg Cobimetinib + 100 mg PictilisibS2 Pancreatic: 40 mg Cobimetinib + 100 mg Pictilisib
Tmax of Pictilisib on Cycle 1 Day 21 - Stage 2 Individual Indication Specific Cohorts4.00 (2.0 to 6.0)2.00 (0.5 to 6.0)2.00 (2.0 to 4.0)NA (NA to NA)
SecondaryCmax of Pictilisib on Cycle 1 Day 21 - Stage 2 Individual Indication Specific Cohorts

Stage 2 PK data were reported for each indication specific cohort separately.

Time frame:
Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 21, Cycle 1 Day 22, Cycle 2 Days 1, 15, 21
Reported as:
Geometric mean · ng/mL
Cmax of Pictilisib on Cycle 1 Day 21 - Stage 2 Individual Indication Specific Cohorts
ng/mLS2 EGFR T790M NSCLC: 40 mg Cobimetinib + 100 mg PictilisibS2 KRAS NSCLC: 40 mg Cobimetinib + 100 mg PictilisibS2 KRAS CRC: 40 mg Cobimetinib + 100 mg PictilisibS2 Pancreatic: 40 mg Cobimetinib + 100 mg Pictilisib
Cmax of Pictilisib on Cycle 1 Day 21 - Stage 2 Individual Indication Specific Cohorts231 ± 63362 ± 60369 ± 66NA ± NA
SecondaryAUC0-24 of Pictilisib on Cycle 1 Day 21 - Stage 2 Individual Indication Specific Cohorts

Stage 2 PK data were reported for each indication specific cohort separately.

Time frame:
Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 21, Cycle 1 Day 22
Reported as:
Geometric mean · ng*h/mL
AUC0-24 of Pictilisib on Cycle 1 Day 21 - Stage 2 Individual Indication Specific Cohorts
ng*h/mLS2 EGFR T790M NSCLC: 40 mg Cobimetinib + 100 mg PictilisibS2 KRAS NSCLC: 40 mg Cobimetinib + 100 mg PictilisibS2 KRAS CRC: 40 mg Cobimetinib + 100 mg PictilisibS2 Pancreatic: 40 mg Cobimetinib + 100 mg Pictilisib
AUC0-24 of Pictilisib on Cycle 1 Day 21 - Stage 2 Individual Indication Specific Cohorts3390 ± 395250 ± 664580 ± 56NA ± NA
Secondaryt1/2 of Pictilisib on Cycle 1 Day 21 - Stage 2 Individual Indication Specific Cohorts

Stage 2 PK data were reported for each indication specific cohort separately. Half-life is the time measured for the plasma concentration to decrease by one half.

Time frame:
Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 21, Cycle 1 Day 22, Cycle 2 Days 1, 15, 21
Reported as:
Geometric mean · hours
t1/2 of Pictilisib on Cycle 1 Day 21 - Stage 2 Individual Indication Specific Cohorts
hoursS2 EGFR T790M NSCLC: 40 mg Cobimetinib + 100 mg PictilisibS2 KRAS NSCLC: 40 mg Cobimetinib + 100 mg PictilisibS2 KRAS CRC: 40 mg Cobimetinib + 100 mg PictilisibS2 Pancreatic: 40 mg Cobimetinib + 100 mg Pictilisib
t1/2 of Pictilisib on Cycle 1 Day 21 - Stage 2 Individual Indication Specific Cohorts183 (NA to NA)28.5 (22 to 33)26.6 (20 to 37)30.9 (NA to NA)
SecondaryCL/F of Pictilisib on Cycle 1 Day 21 - Stage 2 Individual Indication Specific Cohorts

Stage 2 PK data were reported for each indication specific cohort separately. Half-life is the time measured for the plasma concentration to decrease by one half. Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.

Time frame:
Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 21, Cycle 1 Day 22, Cycle 2 Days 1, 15, 21
Reported as:
Geometric mean · L/hr
CL/F of Pictilisib on Cycle 1 Day 21 - Stage 2 Individual Indication Specific Cohorts
L/hrS2 EGFR T790M NSCLC: 40 mg Cobimetinib + 100 mg PictilisibS2 KRAS NSCLC: 40 mg Cobimetinib + 100 mg PictilisibS2 KRAS CRC: 40 mg Cobimetinib + 100 mg PictilisibS2 Pancreatic: 40 mg Cobimetinib + 100 mg Pictilisib
CL/F of Pictilisib on Cycle 1 Day 21 - Stage 2 Individual Indication Specific Cohorts29.5 ± 3919.1 ± 6621.8 ± 56NA ± NA
SecondaryAccumulation Ratio of Pictilisib on Cycle 1 Day 21 - Stage 2 Individual Indication Specific Cohorts

Stage 2 PK data were reported for each indication specific cohort separately. Accumulation ratio was calculated as: AUC0-24 at Cycle 1 Day 21 divided by AUC0-24 at Cycle 1 Day 1.

Time frame:
Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Days 1 and 21, Cycle 1 Days 2 and 22
Reported as:
Geometric mean · ratio
Accumulation Ratio of Pictilisib on Cycle 1 Day 21 - Stage 2 Individual Indication Specific Cohorts
ratioS2 EGFR T790M NSCLC: 40 mg Cobimetinib + 100 mg PictilisibS2 KRAS NSCLC: 40 mg Cobimetinib + 100 mg PictilisibS2 KRAS CRC: 40 mg Cobimetinib + 100 mg PictilisibS2 Pancreatic: 40 mg Cobimetinib + 100 mg Pictilisib
Accumulation Ratio of Pictilisib on Cycle 1 Day 21 - Stage 2 Individual Indication Specific Cohorts0.90 ± 401.39 ± 581.43 ± 57NA ± NA
SecondaryTmax of Cobimetinib on Cycle 1 Day 1 - Stage 2A Individual Indication Specific Cohorts

Stage 2A PK data were reported for each indication specific cohort separately.

Time frame:
Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 1, Cycle 1 Days 2, 8, 15-17
Reported as:
Median · hours
Tmax of Cobimetinib on Cycle 1 Day 1 - Stage 2A Individual Indication Specific Cohorts
hoursS2A EGFR T790M NSCLC: 125 mg Cobimetinib + 180 mg PictilisibS2A KRAS NSCLC: 125 mg Cobimetinib + 180 mg PictilisibS2A KRAS CRC: 125 mg Cobimetinib + 180 mg PictilisibS2A Pancreatic: 125 mg Cobimetinib + 180 mg PictilisibS2A Endometrioid: 125 mg Cobimetinib + 180 mg Pictilisib
Tmax of Cobimetinib on Cycle 1 Day 1 - Stage 2A Individual Indication Specific Cohorts4.00 (NA to NA)6.00 (2.0 to 24.0)4.00 (2.0 to 24)4.00 (2.0 to 24)2.00 (2.0 to 4.0)
SecondaryCmax of Cobimetinib on Cycle 1 Day 1 - Stage 2A Individual Indication Specific Cohorts

Stage 2A PK data were reported for each indication specific cohort separately.

Time frame:
Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 1, Cycle 1 Days 2, 8, 15-17
Reported as:
Geometric mean · ng/mL
Cmax of Cobimetinib on Cycle 1 Day 1 - Stage 2A Individual Indication Specific Cohorts
ng/mLS2A EGFR T790M NSCLC: 125 mg Cobimetinib + 180 mg PictilisibS2A KRAS NSCLC: 125 mg Cobimetinib + 180 mg PictilisibS2A KRAS CRC: 125 mg Cobimetinib + 180 mg PictilisibS2A Pancreatic: 125 mg Cobimetinib + 180 mg PictilisibS2A Endometrioid: 125 mg Cobimetinib + 180 mg Pictilisib
Cmax of Cobimetinib on Cycle 1 Day 1 - Stage 2A Individual Indication Specific Cohorts487 ± NA334 ± 44256 ± 130277 ± 110408 ± 89
SecondaryAUC0-24 of Cobimetinib on Cycle 1 Day 1 - Stage 2A Individual Indication Specific Cohorts

Stage 2A PK data were reported for each indication specific cohort separately.

Time frame:
Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 1, Cycle 1 Days 2
Reported as:
Geometric mean · ng*h/mL
AUC0-24 of Cobimetinib on Cycle 1 Day 1 - Stage 2A Individual Indication Specific Cohorts
ng*h/mLS2A EGFR T790M NSCLC: 125 mg Cobimetinib + 180 mg PictilisibS2A KRAS NSCLC: 125 mg Cobimetinib + 180 mg PictilisibS2A KRAS CRC: 125 mg Cobimetinib + 180 mg PictilisibS2A Pancreatic: 125 mg Cobimetinib + 180 mg PictilisibS2A Endometrioid: 125 mg Cobimetinib + 180 mg Pictilisib
AUC0-24 of Cobimetinib on Cycle 1 Day 1 - Stage 2A Individual Indication Specific Cohorts6560 ± NA5210 ± 434470 ± 1204090 ± 1205630 ± 90
SecondaryTmax of Cobimetinib on Cycle 1 Day 18 - Stage 2A Individual Indication Specific Cohorts

Stage 2A PK data were reported for each indication specific cohort separately. As planned, summary statistics were not derived if fewer than 3 participants had available data; however, if the number of participants analyzed = 1, then the observed data of the single participant was reported as median.

Time frame:
Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 18, Cycle 1 Day 19, Cycle 2 Days 1, 15, 21
Reported as:
Median · hours
Tmax of Cobimetinib on Cycle 1 Day 18 - Stage 2A Individual Indication Specific Cohorts
hoursS2A EGFR T790M NSCLC: 125 mg Cobimetinib + 180 mg PictilisibS2A KRAS NSCLC: 125 mg Cobimetinib + 180 mg PictilisibS2A KRAS CRC: 125 mg Cobimetinib + 180 mg PictilisibS2A Pancreatic: 125 mg Cobimetinib + 180 mg PictilisibS2A Endometrioid: 125 mg Cobimetinib + 180 mg Pictilisib
Tmax of Cobimetinib on Cycle 1 Day 18 - Stage 2A Individual Indication Specific Cohorts4.00 (NA to NA)4.00 (2.0 to 6.0)3.00 (2.0 to 6.0)4.00 (2.0 to 6.0)NA (NA to NA)
SecondaryCmax of Cobimetinib on Cycle 1 Day 18 - Stage 2A Individual Indication Specific Cohorts

Stage 2A PK data were reported for each indication specific cohort separately. As planned, summary statistics were not derived if fewer than 3 participants had available data; however, if the number of participants analyzed = 1, then the observed data of the single participant was reported as geometric mean.

Time frame:
Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 18, Cycle 1 Day 19, Cycle 2 Days 1, 15, 21
Reported as:
Geometric mean · ng/mL
Cmax of Cobimetinib on Cycle 1 Day 18 - Stage 2A Individual Indication Specific Cohorts
ng/mLS2A EGFR T790M NSCLC: 125 mg Cobimetinib + 180 mg PictilisibS2A KRAS NSCLC: 125 mg Cobimetinib + 180 mg PictilisibS2A KRAS CRC: 125 mg Cobimetinib + 180 mg PictilisibS2A Pancreatic: 125 mg Cobimetinib + 180 mg PictilisibS2A Endometrioid: 125 mg Cobimetinib + 180 mg Pictilisib
Cmax of Cobimetinib on Cycle 1 Day 18 - Stage 2A Individual Indication Specific Cohorts587 ± NA502 ± 16469 ± 40393 ± 44NA ± NA
SecondaryAUC0-24 of Cobimetinib on Cycle 1 Day 18 - Stage 2A Individual Indication Specific Cohorts

Stage 2A PK data were reported for each indication specific cohort separately. As planned, summary statistics were not derived if fewer than 3 participants had available data; however, if the number of participants analyzed = 1, then the observed data of the single participant was reported as geometric mean.

Time frame:
Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 18, Cycle 1 Day 19, Cycle 2 Days 1, 15, 21
Reported as:
Geometric mean · ng*h/mL
AUC0-24 of Cobimetinib on Cycle 1 Day 18 - Stage 2A Individual Indication Specific Cohorts
ng*h/mLS2A EGFR T790M NSCLC: 125 mg Cobimetinib + 180 mg PictilisibS2A KRAS NSCLC: 125 mg Cobimetinib + 180 mg PictilisibS2A KRAS CRC: 125 mg Cobimetinib + 180 mg PictilisibS2A Pancreatic: 125 mg Cobimetinib + 180 mg PictilisibS2A Endometrioid: 125 mg Cobimetinib + 180 mg Pictilisib
AUC0-24 of Cobimetinib on Cycle 1 Day 18 - Stage 2A Individual Indication Specific Cohorts9560 ± NA7920 ± 167390 ± 325790 ± 46NA ± NA
Secondaryt1/2 of Cobimetinib on Cycle 1 Day 18 - Stage 2A Individual Indication Specific Cohorts

Stage 2A PK data were reported for each indication specific cohort separately. Half-life is the time measured for the plasma concentration to decrease by one half. As planned, summary statistics were not derived if fewer than 3 participants had available data; however, if the number of participants analyzed = 1, then the observed data of the single participant was reported as geometric mean.

Time frame:
Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 18, Cycle 1 Day 19, Cycle 2 Days 1, 15, 21
Reported as:
Geometric mean · hours
t1/2 of Cobimetinib on Cycle 1 Day 18 - Stage 2A Individual Indication Specific Cohorts
hoursS2A EGFR T790M NSCLC: 125 mg Cobimetinib + 180 mg PictilisibS2A KRAS NSCLC: 125 mg Cobimetinib + 180 mg PictilisibS2A KRAS CRC: 125 mg Cobimetinib + 180 mg PictilisibS2A Pancreatic: 125 mg Cobimetinib + 180 mg PictilisibS2A Endometrioid: 125 mg Cobimetinib + 180 mg Pictilisib
t1/2 of Cobimetinib on Cycle 1 Day 18 - Stage 2A Individual Indication Specific Cohorts37.7 (NA to NA)38.6 (33 to 42)50.2 (35 to 89)42.6 (27 to 64)NA (NA to NA)
SecondaryCL/F of Cobimetinib on Cycle 1 Day 18 - Stage 2A Individual Indication Specific Cohorts

Stage 2A PK data were reported for each indication specific cohort separately. Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood. As planned, summary statistics were not derived if fewer than 3 participants had available data; however, if the number of participants analyzed = 1, then the observed data of the single participant was reported as geometric mean.

Time frame:
Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 18, Cycle 1 Day 19, Cycle 2 Days 1, 15, 21
Reported as:
Geometric mean · L/hr
CL/F of Cobimetinib on Cycle 1 Day 18 - Stage 2A Individual Indication Specific Cohorts
L/hrS2A EGFR T790M NSCLC: 125 mg Cobimetinib + 180 mg PictilisibS2A KRAS NSCLC: 125 mg Cobimetinib + 180 mg PictilisibS2A KRAS CRC: 125 mg Cobimetinib + 180 mg PictilisibS2A Pancreatic: 125 mg Cobimetinib + 180 mg PictilisibS2A Endometrioid: 125 mg Cobimetinib + 180 mg Pictilisib
CL/F of Cobimetinib on Cycle 1 Day 18 - Stage 2A Individual Indication Specific Cohorts13.1 ± NA15.8 ± 1616.9 ± 3221.6 ± 46NA ± NA
SecondaryAccumulation Ratio of Cobimetinib on Cycle 1 Day 18 - Stage 2A Individual Indication Specific Cohorts

Stage 2A PK data were reported for each indication specific cohort separately. Accumulation ratio was calculated as: AUC0-24 at Cycle 1 Day 21 divided by AUC0-24 at Cycle 1 Day 1. As planned, summary statistics were not derived if fewer than 3 participants had available data; however, if the number of participants analyzed = 1, then the observed data of the single participant was reported as geometric mean.

Time frame:
Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 18, Cycle 1 Day 19, Cycle 2 Days 1, 15, 21
Reported as:
Geometric mean · ng*h/mL
Accumulation Ratio of Cobimetinib on Cycle 1 Day 18 - Stage 2A Individual Indication Specific Cohorts
ng*h/mLS2A EGFR T790M NSCLC: 125 mg Cobimetinib + 180 mg PictilisibS2A KRAS NSCLC: 125 mg Cobimetinib + 180 mg PictilisibS2A KRAS CRC: 125 mg Cobimetinib + 180 mg PictilisibS2A Pancreatic: 125 mg Cobimetinib + 180 mg PictilisibS2A Endometrioid: 125 mg Cobimetinib + 180 mg Pictilisib
Accumulation Ratio of Cobimetinib on Cycle 1 Day 18 - Stage 2A Individual Indication Specific Cohorts1.46 ± NA1.43 ± 511.89 ± 941.72 ± 83NA ± NA
SecondaryTmax of Pictilisib on Cycle 1 Day 1 - Stage 2A Individual Indication Specific Cohorts

Stage 2A PK data were reported for each indication specific cohort separately.

Time frame:
Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 1, Cycle 1 Days 2, 8, 15-17
Reported as:
Median · hours
Tmax of Pictilisib on Cycle 1 Day 1 - Stage 2A Individual Indication Specific Cohorts
hoursS2A EGFR T790M NSCLC: 125 mg Cobimetinib + 180 mg PictilisibS2A KRAS NSCLC: 125 mg Cobimetinib + 180 mg PictilisibS2A KRAS CRC: 125 mg Cobimetinib + 180 mg PictilisibS2A Pancreatic: 125 mg Cobimetinib + 180 mg PictilisibS2A Endometrioid: 125 mg Cobimetinib + 180 mg Pictilisib
Tmax of Pictilisib on Cycle 1 Day 1 - Stage 2A Individual Indication Specific Cohorts2.00 (NA to NA)2.00 (0.5 to 6.0)2.00 (0.5 to 6.0)2.00 (0.5 to 24)4.00 (2.0 to 6.0)
SecondaryCmax of Pictilisib on Cycle 1 Day 1 - Stage 2A Individual Indication Specific Cohorts

Stage 2A PK data were reported for each indication specific cohort separately.

Time frame:
Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 1, Cycle 1 Days 2, 8, 15-17
Reported as:
Geometric mean · ng/mL
Cmax of Pictilisib on Cycle 1 Day 1 - Stage 2A Individual Indication Specific Cohorts
ng/mLS2A EGFR T790M NSCLC: 125 mg Cobimetinib + 180 mg PictilisibS2A KRAS NSCLC: 125 mg Cobimetinib + 180 mg PictilisibS2A KRAS CRC: 125 mg Cobimetinib + 180 mg PictilisibS2A Pancreatic: 125 mg Cobimetinib + 180 mg PictilisibS2A Endometrioid: 125 mg Cobimetinib + 180 mg Pictilisib
Cmax of Pictilisib on Cycle 1 Day 1 - Stage 2A Individual Indication Specific Cohorts714 ± NA265 ± 140289 ± 100393 ± 90369 ± 35
SecondaryAUC0-24 of Pictilisib on Cycle 1 Day 1 - Stage 2A Individual Indication Specific Cohorts

Stage 2A PK data were reported for each indication specific cohort separately.

Time frame:
Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 1, Cycle 1 Days 2
Reported as:
Geometric mean · ng*h/mL
AUC0-24 of Pictilisib on Cycle 1 Day 1 - Stage 2A Individual Indication Specific Cohorts
ng*h/mLS2A EGFR T790M NSCLC: 125 mg Cobimetinib + 180 mg PictilisibS2A KRAS NSCLC: 125 mg Cobimetinib + 180 mg PictilisibS2A KRAS CRC: 125 mg Cobimetinib + 180 mg PictilisibS2A Pancreatic: 125 mg Cobimetinib + 180 mg PictilisibS2A Endometrioid: 125 mg Cobimetinib + 180 mg Pictilisib
AUC0-24 of Pictilisib on Cycle 1 Day 1 - Stage 2A Individual Indication Specific Cohorts8050 ± NA3380 ± 1003310 ± 764030 ± 884500 ± 16
SecondaryTmax of Pictilisib on Cycle 1 Day 18 - Stage 2A Individual Indication Specific Cohorts

Stage 2A PK data were reported for each indication specific cohort separately. As planned, summary statistics were not derived if fewer than 3 participants had available data; however, if the number of participants analyzed = 1, then the observed data of the single participant was reported as geometric mean.

Time frame:
Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 18, Cycle 1 Day 19, Cycle 2 Days 1, 15, 21
Reported as:
Median · hours
Tmax of Pictilisib on Cycle 1 Day 18 - Stage 2A Individual Indication Specific Cohorts
hoursS2A EGFR T790M NSCLC: 125 mg Cobimetinib + 180 mg PictilisibS2A KRAS NSCLC: 125 mg Cobimetinib + 180 mg PictilisibS2A KRAS CRC: 125 mg Cobimetinib + 180 mg PictilisibS2A Pancreatic: 125 mg Cobimetinib + 180 mg PictilisibS2A Endometrioid: 125 mg Cobimetinib + 180 mg Pictilisib
Tmax of Pictilisib on Cycle 1 Day 18 - Stage 2A Individual Indication Specific Cohorts2.00 (NA to NA)2.00 (2.0 to 24)2.00 (0.5 to 4.0)2.00 (2.0 to 6.0)NA (NA to NA)
SecondaryCmax of Pictilisib on Cycle 1 Day 18 - Stage 2A Individual Indication Specific Cohorts

Stage 2A PK data were reported for each indication specific cohort separately. As planned, summary statistics were not derived if fewer than 3 participants had available data; however, if the number of participants analyzed = 1, then the observed data of the single participant was reported as geometric mean.

Time frame:
Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 18, Cycle 1 Day 19, Cycle 2 Days 1, 15, 21
Reported as:
Geometric mean · ng/mL
Cmax of Pictilisib on Cycle 1 Day 18 - Stage 2A Individual Indication Specific Cohorts
ng/mLS2A EGFR T790M NSCLC: 125 mg Cobimetinib + 180 mg PictilisibS2A KRAS NSCLC: 125 mg Cobimetinib + 180 mg PictilisibS2A KRAS CRC: 125 mg Cobimetinib + 180 mg PictilisibS2A Pancreatic: 125 mg Cobimetinib + 180 mg PictilisibS2A Endometrioid: 125 mg Cobimetinib + 180 mg Pictilisib
Cmax of Pictilisib on Cycle 1 Day 18 - Stage 2A Individual Indication Specific Cohorts412 ± NA518 ± 67520 ± 84334 ± 83NA ± NA
SecondaryAUC0-24 of Pictilisib on Cycle 1 Day 18 - Stage 2A Individual Indication Specific Cohorts

Stage 2A PK data were reported for each indication specific cohort separately. As planned, summary statistics were not derived if fewer than 3 participants had available data; however, if the number of participants analyzed = 1, then the observed data of the single participant was reported as geometric mean.

Time frame:
Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 18, Cycle 1 Day 19, Cycle 2 Days 1, 15, 21
Reported as:
Geometric mean · ng*h/mL
AUC0-24 of Pictilisib on Cycle 1 Day 18 - Stage 2A Individual Indication Specific Cohorts
ng*h/mLS2A EGFR T790M NSCLC: 125 mg Cobimetinib + 180 mg PictilisibS2A KRAS NSCLC: 125 mg Cobimetinib + 180 mg PictilisibS2A KRAS CRC: 125 mg Cobimetinib + 180 mg PictilisibS2A Pancreatic: 125 mg Cobimetinib + 180 mg PictilisibS2A Endometrioid: 125 mg Cobimetinib + 180 mg Pictilisib
AUC0-24 of Pictilisib on Cycle 1 Day 18 - Stage 2A Individual Indication Specific Cohorts6300 ± NA6310 ± 315930 ± 733990 ± 74NA ± NA
Secondaryt1/2 of Pictilisib on Cycle 1 Day 18 - Stage 2A Individual Indication Specific Cohorts

Stage 2A PK data were reported for each indication specific cohort separately. Half-life is the time measured for the plasma concentration to decrease by one half.

Time frame:
Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 18, Cycle 1 Day 19, Cycle 2 Days 1, 15, 21
Reported as:
Geometric mean · hours
t1/2 of Pictilisib on Cycle 1 Day 18 - Stage 2A Individual Indication Specific Cohorts
hoursS2A EGFR T790M NSCLC: 125 mg Cobimetinib + 180 mg PictilisibS2A KRAS NSCLC: 125 mg Cobimetinib + 180 mg PictilisibS2A KRAS CRC: 125 mg Cobimetinib + 180 mg PictilisibS2A Pancreatic: 125 mg Cobimetinib + 180 mg PictilisibS2A Endometrioid: 125 mg Cobimetinib + 180 mg Pictilisib
t1/2 of Pictilisib on Cycle 1 Day 18 - Stage 2A Individual Indication Specific Cohorts—44.6 (28 to 66)58.2 (40 to 83)37.8 (29 to 50)30.3 (NA to NA)
SecondaryCL/F of Pictilisib on Cycle 1 Day 18 - Stage 2A Individual Indication Specific Cohorts

Stage 2A PK data were reported for each indication specific cohort separately. Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood. As planned, summary statistics were not derived if fewer than 3 participants had available data; however, if the number of participants analyzed = 1, then the observed data of the single participant was reported as geometric mean.

Time frame:
Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 18, Cycle 1 Day 19, Cycle 2 Days 1, 15, 21
Reported as:
Geometric mean · L/hr
CL/F of Pictilisib on Cycle 1 Day 18 - Stage 2A Individual Indication Specific Cohorts
L/hrS2A EGFR T790M NSCLC: 125 mg Cobimetinib + 180 mg PictilisibS2A KRAS NSCLC: 125 mg Cobimetinib + 180 mg PictilisibS2A KRAS CRC: 125 mg Cobimetinib + 180 mg PictilisibS2A Pancreatic: 125 mg Cobimetinib + 180 mg PictilisibS2A Endometrioid: 125 mg Cobimetinib + 180 mg Pictilisib
CL/F of Pictilisib on Cycle 1 Day 18 - Stage 2A Individual Indication Specific Cohorts28.6 ± NA28.5 ± 3130.3 ± 7345.1 ± 74NA ± NA
SecondaryAccumulation Ratio of Pictilisib on Cycle 1 Day 18 - Stage 2A Individual Indication Specific Cohorts

Stage 2A PK data were reported for each indication specific cohort separately. Accumulation ratio was calculated as: AUC0-24 at Cycle 1 Day 21 divided by AUC0-24 at Cycle 1 Day 1. As planned, summary statistics were not derived if fewer than 3 participants had available data; however, if the number of participants analyzed = 1, then the observed data of the single participant was reported as geometric mean.

Time frame:
Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 18, Cycle 1 Day 19, Cycle 2 Days 1, 15, 21
Reported as:
Geometric mean · ng*h/mL
Accumulation Ratio of Pictilisib on Cycle 1 Day 18 - Stage 2A Individual Indication Specific Cohorts
ng*h/mLS2A EGFR T790M NSCLC: 125 mg Cobimetinib + 180 mg PictilisibS2A KRAS NSCLC: 125 mg Cobimetinib + 180 mg PictilisibS2A KRAS CRC: 125 mg Cobimetinib + 180 mg PictilisibS2A Pancreatic: 125 mg Cobimetinib + 180 mg PictilisibS2A Endometrioid: 125 mg Cobimetinib + 180 mg Pictilisib
Accumulation Ratio of Pictilisib on Cycle 1 Day 18 - Stage 2A Individual Indication Specific Cohorts0.78 ± NA1.61 ± 1101.90 ± 501.03 ± 84NA ± NA
SecondaryNumber of Participants With Best Overall Response - Dose Escalation Stages 1, 1A and 1B

Tumor response was assessed using Response Evaluation Criteria in Solid Tumors (RECIST). Complete response (CR) = disappearance of all target and non-target lesions. Partial Response (PR) = at least 30 percent (%) decrease in sum of the longest diameter of measured lesions taking as reference the baseline sum of the longest diameter. Progressive disease (PD) = at least 20% increase in the sum of the longest diameter of measured lesions taking as reference the smallest sum of the longest diameter since treatment start or appearance of one or more new lesions. Stable disease (SD) = neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum of the longest diameter since treatment start.

Time frame:
Up to 30 days after last dose (last dose = up to Cycle 15, cycle length = 28 days)
Reported as:
Number · participants
Number of Participants With Best Overall Response - Dose Escalation Stages 1, 1A and 1B
participantsS1 C1: 20 mg Cobimetinib + 80 mg PictilisibS1 C2: 20 mg Cobimetinib + 100 mg PictilisibS1 C3: 40 mg Cobimetinib + 80 mg PictilisibS1 C4/S2 Expansion: 40 mg Cobimetinib + 100 mg PictilisibS1 C5: 40 mg Cobimetinib + 130 mg PictilisibS1 C6: 60 mg Cobimetinib + 100 mg PictilisibS1 C6A: 80 mg Cobimetinib + 100 mg PictilisibS1A CA: 100 mg Cobimetinib + 130 mg PictilisibS1A CB: 100 mg Cobimetinib + 180 mg PictilisibS1A CC: 125 mg Cobimetinib + 130 mg PictilisibS1A CD/S2A Expension: 125 mg Cobimetinib + 180 mg PictilisibS1A CE: 125 mg Cobimetinib + 245 mg PictilisibS1A CF: 150 mg Cobimetinib + 180 mg PictilisibS1A CG: 150 mg Cobimetinib + 245 mg PictilisibS1B CAX: 40 mg Cobimetinib + 130 mg PictilisibS1B CBX: 40 mg Cobimetinib + 180 mg PictilisibS1B CCX: 60 mg Cobimetinib + 130 mg PictilisibS1B CDX: 60 mg Cobimetinib + 180 mg Pictilisib
PR000001000120000000
SD22115531023165201101
PD01216540210171433232
Unable to Evaluate000000000001000000
SecondaryDuration of Objective Response - Dose Escalation Stages 1, 1A and 1B

Duration of objective response was defined as the time from first occurrence of a documented objective response (CR or PR) until the time of disease progression, as determined by investigator review of tumor assessments using RECIST, or death from any cause during the study (within 30 days after the last dose of study treatment). CR = disappearance of all target and non-target lesions. PR = at least 30 % decrease in sum of the longest diameter of measured lesions taking as reference the baseline sum of the longest diameter. PD = at least 20% increase in the sum of the longest diameter of measured lesions taking as reference the smallest sum of the longest diameter since treatment start or appearance of one or more new lesions.

Time frame:
Up to 30 days after last dose (last dose = up to Cycle 15, cycle length = 28 days)

No measurements were reported for this outcome.

SecondaryProgression-Free Survival (PFS) - Dose Escalation Stages 1, 1A and 1B

PFS was the time from study treatment initiation to the first occurrence of disease progression, as determined by investigator review of tumor assessments using RECIST, or death from any cause during the study (within 30 days after the last dose of study treatment). PD = at least 20% increase in the sum of the longest diameter of measured lesions taking as reference the smallest sum of the longest diameter since treatment start or appearance of one or more new lesions.

Time frame:
Up to 30 days after last dose (last dose = up to Cycle 15, cycle length = 28 days)

No measurements were reported for this outcome.

Adverse events

Collected over Up to 30 days after last dose (last dose = up to Cycle 15, cycle length = 28 days). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
S1 C1: 20 mg Cobimetinib + 80 mg Pictilisib—2/4 (50%)4/4 (100%)
S1 C2: 20 mg Cobimetinib + 100 mg Pictilisib—0/3 (0%)3/3 (100%)
S1 C3: 40 mg Cobimetinib + 80 mg Pictilisib—1/3 (33.3%)3/3 (100%)
S1 C4/S2 Expansion: 40 mg Cobimetinib + 100 mg Pictilisib—25/43 (58.1%)42/43 (97.7%)
S1 C5: 40 mg Cobimetinib + 130 mg Pictilisib—6/11 (54.5%)11/11 (100%)
S1 C6: 60 mg Cobimetinib + 100 mg Pictilisib—6/10 (60%)10/10 (100%)
S1 C6A: 80 mg Cobimetinib + 100 mg Pictilisib—2/4 (50%)4/4 (100%)
S1A CA: 100 mg Cobimetinib + 130 mg Pictilisib—2/3 (66.7%)3/3 (100%)
S1A CB: 100 mg Cobimetinib + 180 mg Pictilisib—2/3 (66.7%)3/3 (100%)
S1A CC: 125 mg Cobimetinib + 130 mg Pictilisib—3/4 (75%)4/4 (100%)
S1A CD/S2A Expension: 125 mg Cobimetinib + 180 mg Pictilisib—28/52 (53.8%)52/52 (100%)
S1A CE: 125 mg Cobimetinib + 245 mg Pictilisib—4/9 (44.4%)9/9 (100%)
S1A CF: 150 mg Cobimetinib + 180 mg Pictilisib—5/8 (62.5%)8/8 (100%)
S1A CG: 150 mg Cobimetinib + 245 mg Pictilisib—3/5 (60%)5/5 (100%)
S1B CAX: 40 mg Cobimetinib + 130 mg Pictilisib—0/4 (0%)4/4 (100%)
S1B CBX: 40 mg Cobimetinib + 180 mg Pictilisib—0/3 (0%)3/3 (100%)
S1B CCX: 60 mg Cobimetinib + 130 mg Pictilisib—0/3 (0%)3/3 (100%)
S1B CDX: 60 mg Cobimetinib + 180 mg Pictilisib—2/5 (40%)5/5 (100%)
Most frequent serious events
Showing 10 of 76
Most frequent serious events
EventS1 C1: 20 mg Cobimetinib + 80 mg PictilisibS1 C2: 20 mg Cobimetinib + 100 mg PictilisibS1 C3: 40 mg Cobimetinib + 80 mg PictilisibS1 C4/S2 Expansion: 40 mg Cobimetinib + 100 mg PictilisibS1 C5: 40 mg Cobimetinib + 130 mg PictilisibS1 C6: 60 mg Cobimetinib + 100 mg PictilisibS1 C6A: 80 mg Cobimetinib + 100 mg PictilisibS1A CA: 100 mg Cobimetinib + 130 mg PictilisibS1A CB: 100 mg Cobimetinib + 180 mg PictilisibS1A CC: 125 mg Cobimetinib + 130 mg PictilisibS1A CD/S2A Expension: 125 mg Cobimetinib + 180 mg PictilisibS1A CE: 125 mg Cobimetinib + 245 mg PictilisibS1A CF: 150 mg Cobimetinib + 180 mg PictilisibS1A CG: 150 mg Cobimetinib + 245 mg PictilisibS1B CAX: 40 mg Cobimetinib + 130 mg PictilisibS1B CBX: 40 mg Cobimetinib + 180 mg PictilisibS1B CCX: 60 mg Cobimetinib + 130 mg PictilisibS1B CDX: 60 mg Cobimetinib + 180 mg Pictilisib
DiarrhoeaGastrointestinal disorders0/40/30/31/430/114/101/40/30/31/43/520/92/80/50/40/30/30/5
Bile duct obstructionHepatobiliary disorders0/40/30/30/430/110/100/40/31/30/40/520/90/80/50/40/30/30/5
PneumoniaInfections and infestations1/40/31/32/430/110/100/40/30/30/42/520/90/80/50/40/30/30/5
SepsisInfections and infestations0/40/30/30/430/110/100/41/30/30/42/520/90/80/50/40/30/30/5
Blood bilirubin increasedInvestigations0/40/30/30/430/110/100/41/30/30/40/520/90/80/50/40/30/30/5
Gastrooesophageal cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/40/30/30/430/110/100/41/30/30/40/520/90/80/50/40/30/30/5
Urinary retentionRenal and urinary disorders0/40/30/30/430/110/100/40/31/30/40/520/90/80/50/40/30/30/5
HypoxiaRespiratory, thoracic and mediastinal disorders0/40/31/30/430/110/100/40/30/30/41/521/90/80/50/40/30/30/5
Urinary tract infectionInfections and infestations0/40/31/30/430/110/100/40/30/30/40/520/90/80/50/40/30/30/5
Cardiac arrestCardiac disorders0/40/30/30/430/110/100/40/30/31/40/520/90/80/50/40/30/30/5
Most frequent other events
Showing 10 of 261
Most frequent other events
EventS1 C1: 20 mg Cobimetinib + 80 mg PictilisibS1 C2: 20 mg Cobimetinib + 100 mg PictilisibS1 C3: 40 mg Cobimetinib + 80 mg PictilisibS1 C4/S2 Expansion: 40 mg Cobimetinib + 100 mg PictilisibS1 C5: 40 mg Cobimetinib + 130 mg PictilisibS1 C6: 60 mg Cobimetinib + 100 mg PictilisibS1 C6A: 80 mg Cobimetinib + 100 mg PictilisibS1A CA: 100 mg Cobimetinib + 130 mg PictilisibS1A CB: 100 mg Cobimetinib + 180 mg PictilisibS1A CC: 125 mg Cobimetinib + 130 mg PictilisibS1A CD/S2A Expension: 125 mg Cobimetinib + 180 mg PictilisibS1A CE: 125 mg Cobimetinib + 245 mg PictilisibS1A CF: 150 mg Cobimetinib + 180 mg PictilisibS1A CG: 150 mg Cobimetinib + 245 mg PictilisibS1B CAX: 40 mg Cobimetinib + 130 mg PictilisibS1B CBX: 40 mg Cobimetinib + 180 mg PictilisibS1B CCX: 60 mg Cobimetinib + 130 mg PictilisibS1B CDX: 60 mg Cobimetinib + 180 mg Pictilisib
DiarrhoeaGastrointestinal disorders3/43/33/339/439/118/104/42/33/34/444/528/97/84/53/42/33/33/5
NauseaGastrointestinal disorders3/42/33/325/436/116/103/41/33/33/436/527/97/83/51/42/31/35/5
StomatitisGastrointestinal disorders0/40/30/311/431/113/102/41/33/32/412/524/91/81/50/40/31/31/5
VomitingGastrointestinal disorders3/40/32/327/435/118/103/42/30/34/432/525/96/83/50/43/31/34/5
Decreased appetiteMetabolism and nutrition disorders2/40/31/316/433/115/101/41/33/34/421/523/95/82/52/41/31/32/5
DysgeusiaNervous system disorders0/41/30/316/433/112/100/42/33/31/416/523/95/82/52/42/31/31/5
RashSkin and subcutaneous tissue disorders0/42/32/39/438/112/103/40/33/32/419/523/91/80/51/40/31/30/5
FatigueGeneral disorders3/41/31/326/435/115/103/41/32/32/429/526/97/83/53/41/32/32/5
HeadacheNervous system disorders2/41/30/37/432/111/100/40/30/30/47/522/90/84/50/40/31/30/5
Rash maculo-papularSkin and subcutaneous tissue disorders0/40/30/316/433/113/100/41/30/31/412/524/93/84/50/41/31/31/5

Baseline characteristics

All enrolled participants.

Age, Continuous
Age, Continuous(years)All Participants
Mean56.6 ± 12.0
Gender
Gender(Participants)All Participants
Female109
Male69
08

Study locations

6 sites
  • Baltimore, Maryland 21231, United States
  • Boston, Massachusetts 02114, United States
  • Boston, Massachusetts 02215, United States
  • Detroit, Michigan 48201, United States
  • Oklahoma City, Oklahoma 73104, United States
  • Nashville, Tennessee 37203, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2009, a primary completion of Mar 2014 and a completion of Mar 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2016, 2 years 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 12, 2009
First posted
Oct 16, 2009
Start
Nov 2009
Primary completionActual
Mar 2014
CompletionActual
Mar 2014
Results first posted
Dec 30, 2016
Last update
Dec 30, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 30, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00996892
Lead sponsor
Genentech, Inc.
Responsible party
Sponsor
First posted
Oct 16, 2009
Start date
Nov 2009
Primary completion
Mar 2014
Completion
Mar 2014
Results posted
Dec 30, 2016
Last update
Dec 30, 2016

Study contacts

Iris Chan, M.D., Ph.D.
study director · Genentech, Inc.
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cobimetinib · Pictilisib

Start the discussion